<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cannabis‐based medicines for chronic neuropathic pain in adults - Mücke, M - 2018 | Cochrane Library</title> <meta content="Cannabis‐based medicines for chronic neuropathic pain in adults - Mücke, M - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cannabis‐based medicines for chronic neuropathic pain in adults - Mücke, M - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012182.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Cannabis‐based medicines for chronic neuropathic pain in adults" name="citation_title"/> <meta content="Martin Mücke" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Tudor Phillips" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Lukas Radbruch" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Frank Petzke" name="citation_author"/> <meta content="Universitätsmedizin Göttingen" name="citation_author_institution"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="whaeuser@klinikum-saarbruecken.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012182.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012182.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Non-Narcotic [adverse effects, *therapeutic use]; Analgesics, Opioid [therapeutic use]; Cannabidiol [adverse effects, therapeutic use]; Chronic Pain [*drug therapy]; Codeine [analogs &amp; derivatives, therapeutic use]; Dronabinol [adverse effects, analogs &amp; derivatives, therapeutic use]; Medical Marijuana [adverse effects, *therapeutic use]; Neuralgia [*drug therapy]; Numbers Needed To Treat; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012182.pub2&amp;doi=10.1002/14651858.CD012182.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012182\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012182\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","pt","ms","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012182.pub2",title:"Cannabis\\u2010based medicines for chronic neuropathic pain in adults",firstPublishedDate:"Mar 7, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012182.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012182.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012182.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012182.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012182.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012182.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012182.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012182.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012182.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012182.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>64863 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012182.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0150"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-sec-0144"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/appendices#CD012182-sec-0162"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/table_n/CD012182StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/table_n/CD012182StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cannabis‐based medicines for chronic neuropathic pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#CD012182-cr-0004">Martin Mücke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#CD012182-cr-0005">Tudor Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#CD012182-cr-0006">Lukas Radbruch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#CD012182-cr-0007">Frank Petzke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information#CD012182-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information/en#CD012182-sec-0169">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012182.pub2">https://doi.org/10.1002/14651858.CD012182.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012182-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012182-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012182-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012182-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012182-abs-0005">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012182-abs-0001" lang="en"> <section id="CD012182-sec-0001"> <h3 class="title" id="CD012182-sec-0001">Background</h3> <p>This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain. </p> </section> <section id="CD012182-sec-0002"> <h3 class="title" id="CD012182-sec-0002">Objectives</h3> <p>To assess the efficacy, tolerability, and safety of cannabis‐based medicines (herbal, plant‐derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults. </p> </section> <section id="CD012182-sec-0003"> <h3 class="title" id="CD012182-sec-0003">Search methods</h3> <p>In November 2017 we searched CENTRAL, MEDLINE, Embase, and two trials registries for published and ongoing trials, and examined the reference lists of reviewed articles. </p> </section> <section id="CD012182-sec-0004"> <h3 class="title" id="CD012182-sec-0004">Selection criteria</h3> <p>We selected randomised, double‐blind controlled trials of medical cannabis, plant‐derived and synthetic cannabis‐based medicines against placebo or any other active treatment of conditions with chronic neuropathic pain in adults, with a treatment duration of at least two weeks and at least 10 participants per treatment arm. </p> </section> <section id="CD012182-sec-0005"> <h3 class="title" id="CD012182-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted data of study characteristics and outcomes of efficacy, tolerability and safety, examined issues of study quality, and assessed risk of bias. We resolved discrepancies by discussion. For efficacy, we calculated the number needed to treat for an additional beneficial outcome (NNTB) for pain relief of 30% and 50% or greater, patient's global impression to be much or very much improved, dropout rates due to lack of efficacy, and the standardised mean differences for pain intensity, sleep problems, health‐related quality of life (HRQoL), and psychological distress. For tolerability, we calculated number needed to treat for an additional harmful outcome (NNTH) for withdrawal due to adverse events and specific adverse events, nervous system disorders and psychiatric disorders. For safety, we calculated NNTH for serious adverse events. Meta‐analysis was undertaken using a random‐effects model. We assessed the quality of evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD012182-sec-0006"> <h3 class="title" id="CD012182-sec-0006">Main results</h3> <p>We included 16 studies with 1750 participants. The studies were 2 to 26 weeks long and compared an oromucosal spray with a plant‐derived combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) (10 studies), a synthetic cannabinoid mimicking THC (nabilone) (two studies), inhaled herbal cannabis (two studies) and plant‐derived THC (dronabinol) (two studies) against placebo (15 studies) and an analgesic (dihydrocodeine) (one study). We used the Cochrane 'Risk of bias' tool to assess study quality. We defined studies with zero to two unclear or high risks of bias judgements to be high‐quality studies, with three to five unclear or high risks of bias to be moderate‐quality studies, and with six to eight unclear or high risks of bias to be low‐quality studies. Study quality was low in two studies, moderate in 12 studies and high in two studies. Nine studies were at high risk of bias for study size<b>.</b> We rated the quality of the evidence according to GRADE as very low to moderate. </p> <p><b>Primary outcomes</b> </p> <p>Cannabis‐based medicines may increase the number of people achieving 50% or greater pain relief compared with placebo (21% versus 17%; risk difference (RD) 0.05 (95% confidence interval (CI) 0.00 to 0.09); NNTB 20 (95% CI 11 to 100); 1001 participants, eight studies, low‐quality evidence). We rated the evidence for improvement in Patient Global Impression of Change (PGIC) with cannabis to be of very low quality (26% versus 21%;RD 0.09 (95% CI 0.01 to 0.17); NNTB 11 (95% CI 6 to 100); 1092 participants, six studies). More participants withdrew from the studies due to adverse events with cannabis‐based medicines (10% of participants) than with placebo (5% of participants) (RD 0.04 (95% CI 0.02 to 0.07); NNTH 25 (95% CI 16 to 50); 1848 participants, 13 studies, moderate‐quality evidence). We did not have enough evidence to determine if cannabis‐based medicines increase the frequency of serious adverse events compared with placebo (RD 0.01 (95% CI ‐0.01 to 0.03); 1876 participants, 13 studies, low‐quality evidence). </p> <p><b>Secondary outcomes</b> </p> <p>Cannabis‐based medicines probably increase the number of people achieving pain relief of 30% or greater compared with placebo (39% versus 33%; RD 0.09 (95% CI 0.03 to 0.15); NNTB 11 (95% CI 7 to 33); 1586 participants, 10 studies, moderate quality evidence). Cannabis‐based medicines may increase nervous system adverse events compared with placebo (61% versus 29%; RD 0.38 (95% CI 0.18 to 0.58); NNTH 3 (95% CI 2 to 6); 1304 participants, nine studies, low‐quality evidence). Psychiatric disorders occurred in 17% of participants using cannabis‐based medicines and in 5% using placebo (RD 0.10 (95% CI 0.06 to 0.15); NNTH 10 (95% CI 7 to 16); 1314 participants, nine studies, low‐quality evidence). </p> <p>We found no information about long‐term risks in the studies analysed.</p> <p><b>Subgroup analyses</b> </p> <p>We are uncertain whether herbal cannabis reduces mean pain intensity (very low‐quality evidence). Herbal cannabis and placebo did not differ in tolerability (very low‐quality evidence). </p> </section> <section id="CD012182-sec-0007"> <h3 class="title" id="CD012182-sec-0007">Authors' conclusions</h3> <p>The potential benefits of cannabis‐based medicine (herbal cannabis, plant‐derived or synthetic THC, THC/CBD oromucosal spray) in chronic neuropathic pain might be outweighed by their potential harms. The quality of evidence for pain relief outcomes reflects the exclusion of participants with a history of substance abuse and other significant comorbidities from the studies, together with their small sample sizes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012182-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012182-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012182-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012182-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012182-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012182-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012182-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012182-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012182-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012182-abs-0002" lang="en"> <h3>Cannabis products for adults with chronic neuropathic pain</h3> <p><b>Bottom line</b> </p> <p>There is a lack of good evidence that any cannabis‐derived product works for any chronic neuropathic pain. </p> <p><b>Background</b> </p> <p>Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from damaged tissue (for example, a fall, or cut, or arthritic knee). Neuropathic pain is treated by different medicines to those used for pain from damaged tissue. </p> <p>Several products based on the cannabis plant have been suggested as treatment for pain, including neuropathic pain. These products include inhaled herbal cannabis, and various sprays or tablets containing active cannabis ingredients obtained from the plant, or made synthetically. </p> <p>Some people with neuropathic pain claim that cannabis‐based products are effective for them, and that is often highlighted in the media.<br/><br/><b>Study characteristics</b> </p> <p>In November 2017 we searched for clinical trials that used cannabis products to treat conditions with chronic neuropathic pain in adults. We found 16 studies involving 1750 people. Studies lasted 2 to 26 weeks. Studies compared different cannabis‐based medicines. Ten studies compared an oromucosal (mouth) spray with a plant‐derived combination of tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, and cannabidiol (CBD), an anti‐inflammatory ingredient of cannabis, against a fake medication (placebo). Two studies each compared inhaled herbal cannabis and cannabis plant‐derived THC with placebo, and one study compared a man‐made cannabinoid mimicking the effects of THC (nabilone) with placebo. One study compared nabilone with a pain killer (dihydrocodeine). </p> <p><b>Key results and quality of the evidence</b> </p> <p>We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low‐quality evidence means that we are very uncertain about the results. High‐quality evidence means that we are very confident in the results. </p> <p>There was no high‐quality evidence.</p> <p>All cannabis‐based medicines pooled together were better than placebo for the outcomes substantial and moderate pain relief and global improvement. All cannabis‐based medicines pooled together were better than placebo in reducing pain intensity, sleep problems and psychological distress (very low‐ to moderate‐quality evidence). </p> <p>There was no difference between all cannabis‐based medicines pooled together and placebo in improving health‐related quality of life, stopping the medication because it was not effective, and in the frequency of serious side effects (low‐quality evidence). </p> <p>More people reported sleepiness, dizziness and mental problems (e.g. confusion) with all cannabis‐based medicines pooled together than with placebo (low‐quality evidence). There was moderate‐quality evidence that more people dropped out due to side effects with cannabis‐based medicines than with placebo. </p> <p>Herbal cannabis was not different from placebo in reducing pain and the number of people who dropped out due to side effects (very low‐quality evidence). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012182-sec-0150" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012182-sec-0150"></div> <h3 class="title" id="CD012182-sec-0151">Implications for practice</h3> <section id="CD012182-sec-0151"> <section id="CD012182-sec-0152"> <h5 class="title">For people with chronic neuropathic pain</h5> <p>There is no high‐quality evidence for the efficacy of any cannabis‐based product including herbal cannabis (marijuana) in any condition with chronic neuropathic pain. Some adverse events (particularly somnolence or sedation, confusion, psychosis) may limit the clinical usefulness of cannabis‐based medicines. It might be expected that, at best, a few people with neuropathic pain will benefit from long‐term use of cannabis‐based medicines. </p> <p>Some current clinical guidelines and systematic reviews consider cannabis‐based medicines as third‐ or fourth‐line therapy for chronic neuropathic pain syndromes if established therapies (e.g. anticonvulsants, antidepressants) have failed (<a href="./references#CD012182-bbs2-0120" title="MoulinD , BoulangerA , ClarkAJ , ClarkeH , DaoT , FinleyGA , et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research &amp; Management2014;19:328-35.">Moulin 2014</a>; <a href="./references#CD012182-bbs2-0124" title="PetzkeF , Enax-KrumovaEK , HäuserW . Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz2016;30:62-88.">Petzke 2016</a>). </p> </section> <section id="CD012182-sec-0153"> <h5 class="title">For physicians</h5> <p>There is no high‐quality evidence for the efficacy of any cannabis‐based medicine (herbal cannabis, plant‐derived THC (dronabinol), synthetic THC (nabilone), plant‐derived THC/CBD combination) in any condition with chronic neuropathic pain. Some adverse events (particularly somnolence or sedation, confusion, psychosis) may limit the clinical usefulness of cannabis‐based medicines. It might be expected that, at best, a few people with neuropathic pain will benefit from long‐term use of cannabis‐based medicines. Since relatively few participants achieve a worthwhile response with cannabis‐based medicines, decisions to use these medicines may require stopping rules to avoid the unnecessary exposure to harms in the absence of benefit. . </p> <p>The Canadian Pain Society recommended cannabis‐based medicines as third‐line therapy for chronic neuropathic pain syndromes if established therapies (e.g. anticonvulsants, antidepressants) had failed (<a href="./references#CD012182-bbs2-0120" title="MoulinD , BoulangerA , ClarkAJ , ClarkeH , DaoT , FinleyGA , et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Research &amp; Management2014;19:328-35.">Moulin 2014</a>). The Special Interest Group on Neuropathic Pain (NeuPSIG) for the pharmacotherapy of neuropathic pain gave a weak recommendation against the use of cannabis‐based medicines (<a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>). </p> <p>The status of approval of cannabis‐based medicines and reimbursement by health insurance companies for chronic pain differs from country to country (<a href="./references#CD012182-bbs2-0035" title="AblinJ , Ste-MariePA , SchäferM , HäuserW , FitzcharlesMA . Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz2016;30:3-13.">Ablin 2016</a>; <a href="./references#CD012182-bbs2-0093" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis- based medicines for chronic pain management and palliative/supportive care in Europe – a survey of the status in the chapters of the European Pain Federation. European Journal Pain2018;22:440-54.">Krcevski‐Skvarc 2018</a>). </p> </section> <section id="CD012182-sec-0154"> <h5 class="title">For policy‐makers</h5> <p>There is no high‐quality evidence suggesting that cannabis‐based medicines (herbal cannabis plant‐derived THC (dronabinol), synthetic THC (nabilone), plant‐derived THC/CBD combination) are of value in treating people with chronic neuropathic pain. This needs to be explained to people requesting this treatment in jurisdictions where it is allowed, e.g. Canada, Germany and Israel. </p> <p>The license of cannabis‐based medicines including herbal cannabis for people with chronic (neuropathic) pain is scheduled for some countries. A patient register to document the efficacy and risks of cannabis‐based medicines financed by public funds is preferable. </p> <p>In the absence of high‐quality evidence of benefit, the use of cannabis‐based medicines at the discretion of a pain specialist with particular expertise in use of cannabis‐based medicines is desirable. Cannabis‐based medicines are no first‐line treatment of any condition with chronic neuropathic pain. </p> </section> <section id="CD012182-sec-0155"> <h5 class="title">For funders</h5> <p>Since no single treatment is effective in a majority of individuals with chronic neuropathic pain, this relatively small number of people with neuropathic pain who benefit from cannabis‐based medicines may be considered worthwhile, particularly if switching rules are in place. The treatment should be supervised by a pain specialist. </p> </section> </section> <h3 class="title" id="CD012182-sec-0156">Implications for research</h3> <section id="CD012182-sec-0156"> <section id="CD012182-sec-0157"> <h5 class="title">General</h5> <p>There may be differences in effect of different cannabis‐based medicines in different types of neuropathic pain. The optimal ratio of THC/CBD still needs to be determined. In addition, pure CBD products or the development of peripherally acting cannabinoid agonists may reduce central nervous system and psychiatric adverse events. To be certain of a result in terms of both direction and magnitude of effect would require very large clinical trials. These trials would need to have important design features. </p> <p> <ol id="CD012182-list-0009"> <li> <p>Chronic neuropathic pain conditions that have not been included in previous trials, such as post‐stroke pain, need to be studied. </p> </li> <li> <p>Study duration with a minimum of three months is recommended.</p> </li> <li> <p>In those clinical conditions for which there is an established treatment option, a three‐arm study (study drug – standard drug treatment‐ placebo) is desirable, in order to allow the assessment of comparative efficacy and safety. </p> </li> <li> <p>Outcomes of clinical utility, such as moderate and substantial benefit using neuropathic pain scales and Patient Global Impression of Change scale (PGIC), are recommended. </p> </li> <li> <p>Imputation method are to be abandoned, as the outcome desired is that of adequate pain relief in the longer term, and for that people have to continue on therapy. Withdrawal for any reason has to be classified as treatment failure. </p> </li> <li> <p>It is preferable that the study protocol defines that treating people with cannabis‐based medicines who do not have pain relief is unacceptable, so that there would be built‐in stopping rules linked to pain relief after an adequate trial of therapy. </p> </li> <li> <p>It is valuable to design and analyse studies whether there are any predisposing features linked with treatment success or failure. </p> </li> <li> <p>Study data have to be made available for review authors for individual participant data analyses. </p> </li> <li> <p>Reporting the details of the assessment of adverse events (spontaneous reports, open questions, symptom questionnaires) is mandatory because the type and frequency of adverse events is influenced by the modes of assessment (<a href="./references#CD012182-bbs2-0081" title="HäuserW , BartramC , Bartram-WunnE , TölleT . Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review. Clinical Journal of Pain2012;28:437-51.">Häuser 2012</a>). Adverse events have to be reported using the International Conference on Harmonization guidelines, and coded within organ classes using the Medical Dictionary for Regulatory Activities (<a href="./references#CD012182-bbs2-0085" title="International Council for Harmonisation. Medical Dictionary for Regulatory Activities Version 19.1. www.meddra.org/news-and-events/news/all-translations-meddra-version-191-are-now-available2016.">International Council for Harmonisation 2016</a>). It is desirable that regulatory agencies standardise the assessment strategies of adverse events in randomised controlled trials. </p> </li> </ol> </p> </section> <section id="CD012182-sec-0158"> <h5 class="title">Design</h5> <p>The key question is whether there are any people with neuropathic pain who do well on cannabis‐based medicines in the long term; that is, with a substantial reduction in pain and/or improvement of daily functioning maintained and tolerable adverse events. An alternative to clinical trials might be the use of registry studies. </p> </section> <section id="CD012182-sec-0159"> <h5 class="title">Measurement (endpoints)</h5> <p>Reporting of average pain changes is inadequate, and the use of responder analyses (pain relief of 50% or greater or participants experiencing mild or no pain) is preferred. </p> <p>The contextual details (e.g. type of pain (average, worst, least, current), time period to be rated, location of pain) of their administration are typically not standardised, nor well‐reported in the literature, resulting in trial results that are challenging to interpret. In an effort to standardise pain intensity assessment. The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public‐private partnership has developed a training system for participants in clinical trials using a zero to 10 numerical rating scale (NRS) to rate pain intensity (<a href="./references#CD012182-bbs2-0130" title="SmithSM , AmtmannD , AskewRL , GewandterJS , HunsingerM , JensenMP , et al. Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system. Pain2016;157(5):1056-64.">Smith 2016</a>). </p> <p>The use of validated neuropathic pain scales and the reports of the effects of cannabis‐based medicines on all items of the neuropathic pain scale are recommended. In addition, a subgrouping of participants with neuropathic syndromes based on sensory profiles is possible and may be useful in clinical trial design to enrich the study population for treatment responders (<a href="./references#CD012182-bbs2-0042" title="BaronR , MaierC , AttalN , BinderA , BouhassiraD , CruccuG , et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain2017;158:261-72.">Baron 2017</a>). </p> <p>Long‐term studies aiming to capture data on misuse and abuse of cannabis‐based medicines and cannabis‐induced mental disorders are valuable. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012182-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012182-sec-0008"></div> <div class="table" id="CD012182-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo for chronic neuropathic pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cannabis‐based medicines compared with placebo for chronic neuropathic pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with chronic neuropathic pain </p> <p><b>Settings</b>: outpatient study centres and hospitals in Europe and North America </p> <p><b>Intervention</b>: cannabis‐based medicines (smoked cannabis; oral plant‐based (dronabinol) or synthetic tetrahydrocannabinol (THC) (nabilone); oromucosal spray of THC and cannabidiol (CBD)) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with intervention</b> </p> <p><b>95% CI</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect</b> </p> <p><b>Risk difference</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief of 50% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1000</p> <p>(196 to 222)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.00 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1001 (8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 20 (11 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change much or very much improved</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000</p> <p>(246 to 276)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.01 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1092 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (6 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(99 to 107)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.02 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1848 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 25 (16 to 50)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> <p>(63 to 69)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (‐0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1876 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not calculated</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief of 30% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>377 per 1000</p> <p>(358 to 396)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>304 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (0.03 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1586 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 11 (7 to 33)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events:</b> <b>nervous system disorder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>611 per 1000</p> <p>(576 to 644)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.18 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 3 (2 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events:</b> <b>psychiatric disorders</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000</p> <p>(156 to 174)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.06 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1314 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 10 (7 to 16)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Abbreviations</b> : <br/><b>CI</b> : Confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RD</b>: risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b>: we are very confident that the true effect lies close to that of the estimate of the effect; </p> <p><b>Moderate quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different; </p> <p><b>Low quality</b>: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> <p><b>Very low quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded once: indirectness. People with current or historical substance abuse, or both, and major medical diseases excluded.<br/><sup>2</sup> Downgraded once: imprecision. CI included zero.<br/><sup>3</sup> Downgraded once: inconsistency. I²&gt;50%. </p> <p><sup>4</sup> Downgraded once: Publication bias. All studies funded by the manufacturer of the drug. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012182-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012182-sec-0009"></div> <p>The protocol for this review was based on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012182-bbs2-0106" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>; <a href="./references#CD012182-bbs2-0112" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012</a>; <a href="./appendices#CD012182-sec-0163">Appendix 1</a>). </p> <section id="CD012182-sec-0010"> <h3 class="title" id="CD012182-sec-0010">Description of the condition</h3> <p>The 2011 International Association for the Study of Pain definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (<a href="./references#CD012182-bbs2-0086" title="JensenTS , BaronR , HaanpääM , KalsoE , LoeserJD , RiceAS , et al. A new definition of neuropathic pain. Pain2011;152(10):2204-5. [DOI: 10.1016/j.pain.2011.06.017]">Jensen 2011</a>), and based on a definition agreed at an earlier consensus meeting (<a href="./references#CD012182-bbs2-0139" title="TreedeRD , JensenTS , CampbellJN , CruccuG , DostrovskyJO , GriffinJW , et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology2008;70(18):1630-5. [DOI: 10.1212/01.wnl.0000282763.29778.59]">Treede 2008</a>). Neuropathic pain is a consequence of a pathological maladaptive response of the nervous system to 'damage' from a wide variety of potential causes. It is characterised by pain in the absence of a noxious stimulus and may be spontaneous (continuous or paroxysmal) in its temporal characteristics or be evoked by sensory stimuli (dynamic mechanical allodynia where pain is evoked by light touch of the skin). Neuropathic pain is associated with a variety of sensory loss (numbness) and sensory gain (allodynia) clinical phenomena, the exact pattern of which vary between people and disease, perhaps reflecting different pain mechanisms operating in an individual person and, therefore, potentially predictive of response to treatment (<a href="./references#CD012182-bbs2-0055" title="DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain2014;155(11):2263-73. [DOI: 10.1016/j.pain.2014.08.014]">Demant 2014</a>; <a href="./references#CD012182-bbs2-0075" title="HelfertSM , ReimerM , HöperJ , BaronR . Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics2015;97(2):135-42. [DOI: 10.1002/cpt.19]">Helfert 2015</a>; <a href="./references#CD012182-bbs2-0144" title="vonHehnCA , BaronR , WoolfCJ . Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008]">von Hehn 2012</a>). Pre‐clinical research hypothesises a bewildering array of possible pain mechanisms that may operate in people with neuropathic pain, which largely reflect pathophysiological responses in both the central and peripheral nervous systems, including neuronal interactions with immune cells (<a href="./references#CD012182-bbs2-0041" title="BaronR , WasnerG , BinderA . Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology2012;11(1):19-21. [DOI: 10.1016/S1474-4422(11)70281-]">Baron 2012</a>; <a href="./references#CD012182-bbs2-0048" title="CalvoM , DawesJM , BennettDL . The role of the immune system in the generation of neuropathic pain. Lancet Neurology2012;11(7):629-42. [DOI: 10.1016/S1474-4422(12)70134-5]">Calvo 2012</a>; <a href="./references#CD012182-bbs2-0144" title="vonHehnCA , BaronR , WoolfCJ . Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron2012;73(4):638-52. [DOI: 10.1016/j.neuron.2012.02.008]">von Hehn 2012</a>). Overall, the treatment gains in neuropathic pain, to even the most effective of available drugs, are modest (<a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>; <a href="./references#CD012182-bbs2-0113" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anesthesia2013;68:400-12.">Moore 2013a</a>), and a robust classification of neuropathic pain is not yet available (<a href="./references#CD012182-bbs2-0064" title="FinnerupNB , ScholzJ , AttalN , BaronR , HaanpääM , HanssonP , et al. Neuropathic pain needs systematic classification. European Journal of Pain2013;17(7):953-6. [DOI: 10.1002/j.1532-2149.2012.00282.x]">Finnerup 2013</a>). </p> <p>Neuropathic pain is usually divided according to the cause of nerve injury. There may be many causes, but some common causes of neuropathic pain include diabetes (painful diabetic neuropathy (PDN)), shingles (postherpetic neuralgia), amputation (stump and phantom limb pain), neuropathic pain after surgery or trauma, stroke or spinal cord injury, trigeminal neuralgia, and HIV infection. Sometimes the cause is unknown. </p> <p>Many people with neuropathic pain conditions are significantly disabled with moderate or severe pain for many years. Chronic pain conditions comprised five of the 11 top‐ranking conditions for years lived with disability in 2010 (<a href="./references#CD012182-bbs2-0145" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]">Vos 2012</a>), and are responsible for considerable loss of quality of life and employment, and increased healthcare costs (<a href="./references#CD012182-bbs2-0115" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94. [DOI: 10.1111/papr.12050]">Moore 2014a</a>). A study in the USA found that healthcare costs were three‐fold higher for people with neuropathic pain than matched control participants (<a href="./references#CD012182-bbs2-0043" title="BergerA , DukesEM , OsterG . Clinical characteristics and economic costs of patients with painful neuropathic disorders. Journal of Pain2004;5(3):143-9. [DOI: 10.1016/j.jpain.2003.12.004]">Berger 2004</a>). A UK study and a German study showed a two‐ to three‐fold higher level of use of healthcare services in people with neuropathic pain than those without (<a href="./references#CD012182-bbs2-0044" title="BergerA , ToelleT , SadoskyA , DukesE , EdelsbergJ , OsterG . Clinical and economic characteristics of patients with painful neuropathic disorders in Germany. Pain Practice2009;9(1):8-17. [DOI: 10.1111/j.1533-2500.2008.00244.x]">Berger 2009</a>; <a href="./references#CD012182-bbs2-0045" title="BergerA , SadoskyA , DukesE , EdelsbergJ , OsterG . Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurology2012;12:8.">Berger 2012</a>). For postherpetic neuralgia, for example, studies demonstrate a large loss of quality of life and substantial costs (<a href="./references#CD012182-bbs2-0129" title="ScottFT , JohnsonRW , Leedham-GreenM , DaviesE , EdmundsWJ , BreuerJ . The burden of herpes zoster: a prospective population based study. Vaccine2006;24(9):1308-14. [DOI: 10.1016/j.vaccine.2005.09.026]">Scott 2006</a>; <a href="./references#CD012182-bbs2-0142" title="Van HoekAJ , GayN , MelegaroA , OpsteltenW , EdmundsWJ . Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine2009;27(9):1454-67. [DOI: 10.1016/j.vaccine.2008.12.024]">Van Hoek 2009</a>). </p> <p>In systematic reviews, the overall prevalence of neuropathic pain in the general population is reported to be between 7% and 10% (<a href="./references#CD012182-bbs2-0141" title="Van HeckeO , AustinSK , KhanRA , SmithBH , TorranceN . Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain2014;155:654-62.">Van Hecke 2014</a>), and about 7% in a systematic review of studies published since 2000 (<a href="./references#CD012182-bbs2-0115" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94. [DOI: 10.1111/papr.12050]">Moore 2014a</a>). In individual countries, prevalence rates have been reported as 3.3% in Austria (<a href="./references#CD012182-bbs2-0071" title="GustorffB , DornerT , LikarR , GrisoldW , LawrenceK , SchwarzF , et al. Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica2008;52:132-6.">Gustorff 2008</a>), 6.9% in France (<a href="./references#CD012182-bbs2-0046" title="BouhassiraD , Lantéri-MinetM , AttalN , LaurentB , TouboulC . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136:380-7.">Bouhassira 2008</a>), and up to 8% in the UK (<a href="./references#CD012182-bbs2-0138" title="TorranceN , SmithBH , BennettMI , LeeAJ . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7:281-9.">Torrance 2006</a>). Some forms of neuropathic pain, such as PDN and post‐surgical chronic pain (which is often neuropathic in origin), are increasing (<a href="./references#CD012182-bbs2-0074" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice2008;9:26.">Hall 2008</a>). </p> <p>Estimates of incidence vary between individual studies for particular origins of neuropathic pain, often because of small numbers of cases. In primary care in the UK, between 2002 and 2005, the incidences (per 100,000 person‐years' observation) were 28 (95% confidence interval (CI), 27 to 30) for PHN, 27 (95% CI, 26 to 29) for trigeminal neuralgia, 0.8 (95% CI, 0.6 to 1.1) for phantom limb pain, and 21 (95% CI, 20 to 22) for PDN (<a href="./references#CD012182-bbs2-0074" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice2008;9:26.">Hall 2008</a>). Other studies have estimated an incidence of 4 in 100,000 per year for trigeminal neuralgia (<a href="./references#CD012182-bbs2-0090" title="KatusicS , WilliamsDB , BeardCM , BergstralhEJ , KurlandLT . Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945-1984. Neuroepidemiology1991;10:276-81.">Katusic 1991</a>; <a href="./references#CD012182-bbs2-0125" title="RappaportZH , DevorM . Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain1994;56:127-38.">Rappaport 1994</a>), and 12.6 per 100,000 person‐years for trigeminal neuralgia and 3.9 per 100,000 person‐years for PHN in a study of facial pain in the Netherlands (<a href="./references#CD012182-bbs2-0091" title="KoopmanJS , DielemanJP , HuygenFJ , De MosM , MartinCG , SturkenboomMC . Incidence of facial pain in the general population. Pain2009;147:122-7.">Koopman 2009</a>). One systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as PDN, can be more common than other neuropathic pain conditions, with prevalence rates up to 400 per 100,000 person‐years (<a href="./references#CD012182-bbs2-0100" title="McQuayHJ , SmithLA , MooreRA . Chronic pain. In: In: Stevens A, Raftery J, Mant J, Simpson S, editor(s). Health Care Needs Assessment, 3rd Series. Radcliffe Publishing, 2007.">McQuay 2007</a>). </p> <p>Neuropathic pain is difficult to treat effectively, with only a minority of people experiencing a clinically relevant benefit from any one intervention (<a href="./references#CD012182-bbs2-0089" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339.">Kalso 2013</a>; <a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). A multidisciplinary approach is now advocated, combining pharmacological interventions with physical or cognitive (or both) interventions. The evidence for interventional management is very weak, or non‐existent (<a href="./references#CD012182-bbs2-0060" title="DworkinRH , O'ConnorAB , KentJ , MackeySC , RajaSN , StaceyBR , et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain2013;154:2249-61.">Dworkin 2013</a>). Conventional analgesics such as paracetamol and nonsteroidal anti‐inflammatory drugs (NSAIDs) are not thought to be effective, but without evidence to support or refute that view (<a href="./references#CD012182-bbs2-0117" title="MooreRA , ChiCC , WiffenPJ , DerryS , RiceASC . Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD010902. [DOI: 10.1002/14651858.CD010902.pub2]">Moore 2015a</a>). Some people may derive some benefit from a topical lidocaine patch or low‐concentration topical capsaicin, although evidence about benefits is uncertain (<a href="./references#CD012182-bbs2-0056" title="DerryS , MooreRA . Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD010111. [DOI: 10.1002/14651858.CD010111]">Derry 2012</a>; <a href="./references#CD012182-bbs2-0057" title="DerryS , WiffenPJ , MooreRA , QuinlanJ . Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD010958. [DOI: 10.1002/14651858.CD010958.pub2]">Derry 2014</a>). High‐concentration topical capsaicin may benefit some people with PHN (<a href="./references#CD012182-bbs2-0058" title="DerryS , RiceASC , ColeP , TanT , MooreRA . Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD007393. [DOI: 10.1002/14651858.CD007393.pub4]">Derry 2017</a>). Treatment is often by so‐called pain modulators such as antidepressants (duloxetine and amitriptyline; <a href="./references#CD012182-bbs2-0097" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3]">Lunn 2014</a>; <a href="./references#CD012182-bbs2-0119" title="WiffenPJ , DerryS , BellRF , RiceASC , TölleTR , PhillipsT , et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2017, Issue 6. Art. No: CD007938. [DOI: 10.1002/14651858.CD007938.pub4]">Moore 2017</a>; <a href="./references#CD012182-bbs2-0118" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub3]">Moore 2015b</a>; <a href="./references#CD012182-bbs2-0135" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology2008;8:29. [DOI: 10.1186/1471-2377-8-]">Sultan 2008</a>), or antiepileptics (gabapentin or pregabalin; <a href="./references#CD012182-bbs2-0105" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub2]">Moore 2009</a>; <a href="./references#CD012182-bbs2-0116" title="MooreRA , CaiN , SkljarevskiV , TölleTR . Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]">Moore 2014b</a>; <a href="./references#CD012182-bbs2-0148" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). Evidence for efficacy of opioids is unconvincing (<a href="./references#CD012182-bbs2-0068" title="GaskellH , DerryS , StannardC , MooreRA . Oxycodone for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD010692. [DOI: 10.1002/14651858.CD010692.pub3]">Gaskell 2016</a>; <a href="./references#CD012182-bbs2-0131" title="SommerC , WelschP , KloseP , SchaefertR , PetzkeF , HäuserW . Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration [Opioide bei chronischem neuropathischem schmerz. Systematische übersicht und metaanalyse der wirksamkeit, verträglichkeit und sicherheit in randomisierten, placebokontrollierten studien über mindestens 4 wochen]. Schmerz2015;29:35-46.">Sommer 2015</a>; <a href="./references#CD012182-bbs2-0132" title="StannardC , GaskellH , DerryS , AldingtonD , ColeP , CooperTE , et al. Hydromorphone for neuropathic pain in adults. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD011604. [DOI: 10.1002/14651858.CD011604.pub2]">Stannard 2016</a>). </p> <p>The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction; <a href="./references#CD012182-bbs2-0113" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anesthesia2013;68:400-12.">Moore 2013a</a>) is small, generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNTB) usually between 4 and 10 (<a href="./references#CD012182-bbs2-0089" title="KalsoE , AldingtonDJ , MooreRA . Drugs for neuropathic pain. BMJ2013;347:f7339.">Kalso 2013</a>; <a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). Neuropathic pain is not particularly different from other chronic pain conditions in that only a small proportion of trial participants have a good response to treatment (<a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). </p> <p>The current National Institute for Health and Care Excellence (NICE) guidance for the pharmacological management of neuropathic pain suggests offering a choice of amitriptyline, duloxetine, gabapentin, or pregabalin as initial treatment for neuropathic pain (with the exception of trigeminal neuralgia), with switching if the first, second, or third drugs tried are not effective or not tolerated (<a href="./references#CD012182-bbs2-0121" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 19 October 2014).">NICE 2013</a>). This concurs with other recent guidelines (<a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>). </p> <p>There is a need to explore other treatment options, with different mechanisms of action and from different drug categories, for treatment of neuropathic pain syndromes. Medical cannabis has been promoted by some patient organisations and advocates for the treatment of chronic pain refractory to conventional treatment and is available for pain management in some countries of the world, e.g. Canada and Israel (<a href="./references#CD012182-bbs2-0035" title="AblinJ , Ste-MariePA , SchäferM , HäuserW , FitzcharlesMA . Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz2016;30:3-13.">Ablin 2016</a>). However, the use of cannabis for medical reasons is highly contested because of the adverse health effects of long‐term cannabis use for recreational purposes (<a href="./references#CD012182-bbs2-0143" title="VolkowND , BalerRD , ComptonWM , WeissSR . Adverse health effects of marijuana use. New England Journal of Medicine2014;370:2219-27.">Volkow 2014</a>). </p> </section> <section id="CD012182-sec-0011"> <h3 class="title" id="CD012182-sec-0011">Description of the intervention</h3> <p>The cannabinoid system is ubiquitous in the animal kingdom, with multiple functions that move the organism back to equilibrium. A large body of evidence currently supports the presence of cannabinoid (CB) receptors and ligands in the peripheral and central nervous system, but also in other tissues such as bone and in the immune system (<a href="./references#CD012182-bbs2-0123" title="OwensB . Drug development: the treasure chest. Nature2015;525:S6-S8.">Owens 2015</a>). </p> <p>The endocannabinoid system has three broad and overlapping functions in mammals. The first is a stress recovery role, operating in a feedback loop in which endocannabinoid signalling is activated by stress and functions to return endocrine, nervous, and behavioural systems to homeostatic balance. The second is to control energy balance through regulation of the intake, storage, and utilisation of food. The third involves immune regulation; endocannabinoid signalling is activated by tissue injury and modulates immune and inflammatory responses (<a href="./references#CD012182-bbs2-0079" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29.">Hillard 2012</a>). Thus, the endocannabinoid neuromodulatory system appears to be involved in multiple physiological functions, such as anti‐nociception, cognition and memory, endocrine function, nausea and vomiting, inflammation, and immune recognition (<a href="./references#CD012182-bbs2-0052" title="De VriesM , Van RijckevorselDC , Wilder-SmithOH , Van GoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">De Vries 2014</a>; <a href="./references#CD012182-bbs2-0079" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29.">Hillard 2012</a>). <i>Cannabis</i> is a genus of the flowering plant in the family Cannabaceae. The number of species within the genus is disputed. Three species may be recognized, <i>Cannabis sativa</i> , <i>Cannabis indica</i> and <i>Cannabis ruderalis</i>. These plants, commonly known as marijuana, have been used for pain relief for millennia, and have additional effects on appetite, sleep, and mood (<a href="./references#CD012182-bbs2-0088" title="KalantH . Medicinal use of cannabis: history and current status. Pain Research &amp; Management2001;6:80-91.">Kalant 2001</a>). Data from clinical trials with synthetic and plant‐based cannabis‐based medicines suggest a promising approach for the management of chronic neuropathic pain of different origins (<a href="./references#CD012182-bbs2-0052" title="De VriesM , Van RijckevorselDC , Wilder-SmithOH , Van GoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34.">De Vries 2014</a>; <a href="./references#CD012182-bbs2-0087" title="JensenB , ChenJ , FurnishT , WallaceM . Medical marijuana and chronic pain: a review of basic science and clinical evidence. Current Pain Headache Reports2015;19:524.">Jensen 2015</a>). </p> </section> <section id="CD012182-sec-0012"> <h3 class="title" id="CD012182-sec-0012">How the intervention might work</h3> <p><i>Cannabis</i> contains over 450 compounds, with at least 70 classified as phytocannabinoids. Two are of particular medical interest. Delta 9‐tetrahydrocannabinol (delta 9‐THC) is the main active constituent, with psychoactive (e.g. reduction of anxiety and stress) and pain‐relieving properties. The second molecule of interest is cannabidiol (CBD), which has lower affinity for the cannabinoid (CB) receptors and the potential to counteract the negative effects of THC on memory, mood, and cognition, but also has an effect on pain modulation by anti‐inflammatory properties. The specific roles of currently identified endocannabis‐based medicines that act as ligands at CB receptors within the nervous system (primarily but not exclusively CB 1 receptors) and in the periphery (primarily but not exclusively CB 2 receptors) are only partially elucidated, but there are abundant pre‐clinical data to support their influence on nociception (<a href="./references#CD012182-bbs2-0123" title="OwensB . Drug development: the treasure chest. Nature2015;525:S6-S8.">Owens 2015</a>). </p> <p>It is also hypothesised that cannabis reduces alterations in cognitive and autonomic processing in chronic pain states (<a href="./references#CD012182-bbs2-0070" title="GuindonJ , HohmannAG . The endocannabinoid system and pain. CNS &amp; Neurological Disorders Drug Targets2009;8:403-29.">Guindon 2009</a>). The frontal‐limbic distribution of CB receptors in the brain suggests that cannabis may preferentially target the affective qualities of pain (<a href="./references#CD012182-bbs2-0095" title="LeeMC , PlonerM , WiechK , BingelU , WanigasekeraV , BrooksJ , et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain2013;134:123-34.">Lee 2013</a>). In addition, cannabis may attenuate low‐grade inflammation, another postulate for the pathogenesis of neuropathic pain (<a href="./references#CD012182-bbs2-0150" title="ZhangJ , EcheverryS , LimTK , LeeSH , ShiXQ , HuangH . Can modulating inflammatory response be a good strategy to treat neuropathic pain?Current Pharmaceutical Design2015;21:831-9.">Zhang 2015</a>). </p> <p>The content of THC and CBD in medical cannabis is highly variable and ranges from 1% to 22% THC and 0.05% to 9% CBD. In contrast the THC/CBD concentration in THC/CBD (nabiximols) oromucosal spray and the THC content in plant‐derived and synthetic THC are standardised (<a href="./references#CD012182-bbs2-0083" title="HäuserW , FitzcharlesMA , RadbruchL , PetzkeF . Efficacy, tolerability and safety of cannabinoids in pain medicine and palliative care: an overview of systematic reviews and of prospective observational studies. Deutsches Ärzteblatt International2017;114:627-34.">Häuser 2017</a>). </p> <p>Taking into consideration the poorly understood pathogenesis of chronic neuropathic pain syndromes, the complexity of symptom expression, and the absence of an ideal treatment, the potential for manipulation of the cannabinoid system as a therapeutic modality is attractive. </p> </section> <section id="CD012182-sec-0013"> <h3 class="title" id="CD012182-sec-0013">Why it is important to do this review</h3> <p>While recent guidance tends to be generally in agreement about the role of antidepressants and anticonvulsants in the management of chronic neuropathic pain (<a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>; <a href="./references#CD012182-bbs2-0121" title="National Institute for Health and Care Excellence (NICE). Neuropathic pain - pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 19 October 2014).">NICE 2013</a>), the role of opioids (<a href="./references#CD012182-bbs2-0131" title="SommerC , WelschP , KloseP , SchaefertR , PetzkeF , HäuserW . Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration [Opioide bei chronischem neuropathischem schmerz. Systematische übersicht und metaanalyse der wirksamkeit, verträglichkeit und sicherheit in randomisierten, placebokontrollierten studien über mindestens 4 wochen]. Schmerz2015;29:35-46.">Sommer 2015</a>) and of cannabis‐based medicines (<a href="./references#CD012182-bbs2-0083" title="HäuserW , FitzcharlesMA , RadbruchL , PetzkeF . Efficacy, tolerability and safety of cannabinoids in pain medicine and palliative care: an overview of systematic reviews and of prospective observational studies. Deutsches Ärzteblatt International2017;114:627-34.">Häuser 2017</a>, <a href="./references#CD012182-bbs2-0084" title="HäuserW , PetzkeF , FitzcharlesMA . Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews. European Journal of Pain2018;22:455-70.">Häuser 2018</a>) is under debate. Recent systematic reviews on the use of cannabis‐based medicines to treat chronic pain came to different conclusions on their importance in chronic neuropathic pain (<a href="./references#CD012182-bbs2-0047" title="BoychukDG , GoddardG , MauroG , OrellanaMF . The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral and Facial Pain and Headache2015;29(1):7-14.">Boychuk 2015</a>; <a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>; <a href="./references#CD012182-bbs2-0124" title="PetzkeF , Enax-KrumovaEK , HäuserW . Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz2016;30:62-88.">Petzke 2016</a>; <a href="./references#CD012182-bbs2-0147" title="WhitingPF , WolffRF , DeshpandeS , Di NisioM , DuffyS . Cannabinoids for medical use: a systematic review and meta-analysis. JAMA2015;313:2456-73.">Whiting 2015</a>). This was probably due to the inclusion of different trials, different standards to evaluate the quality of evidence, and different weighting of the outcomes of efficacy, tolerability, and safety. Due to the conflicting conclusions of recent systematic reviews on the importance of cannabis‐based medicines in treating chronic neuropathic pain, as well as the public debate on the medical use of herbal cannabis for chronic pain (<a href="./references#CD012182-bbs2-0035" title="AblinJ , Ste-MariePA , SchäferM , HäuserW , FitzcharlesMA . Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz2016;30:3-13.">Ablin 2016</a>; <a href="./references#CD012182-bbs2-0066" title="FitzcharlesMA , ClauwDJ , Ste-MariePA , ShirY . The dilemma of medical marijuana use by rheumatology patients. Arthritis Care and Research2014;66:797-801.">Fitzcharles 2014</a>), we saw the need for a Cochrane Review applying the standards of Cochrane Pain, Palliative and Supportive Care (PaPaS). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012182-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012182-sec-0014"></div> <p>To assess the efficacy, tolerability, and safety of cannabis‐based medicines (herbal, plant‐based, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012182-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012182-sec-0015"></div> <section id="CD012182-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012182-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included studies if they were randomised, double‐blind, controlled trials (RCTs) of at least two weeks' duration (drug titration and maintenance or withdrawal). We included studies with a parallel, cross‐over, and enriched enrolment randomised withdrawal (EERW) design with at least 10 participants per treatment arm. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials, and abstracts with sufficient data for analysis. We did not include short abstracts. We excluded studies that were not randomised, studies of experimental pain, case reports, and clinical observations. We included studies that reported at least one outcome of efficacy and one of safety as defined below. </p> </section> <section id="CD012182-sec-0018"> <h4 class="title">Types of participants</h4> <p>Studies included adults aged 18 years and above with one or more chronic (three months and more) neuropathic pain condition including (but not limited to): </p> <p> <ol id="CD012182-list-0001"> <li> <p>cancer‐related neuropathy;</p> </li> <li> <p>central neuropathic pain (e.g. multiple sclerosis);</p> </li> <li> <p>complex regional pain syndrome (CRPS) Type II;</p> </li> <li> <p>HIV neuropathy;</p> </li> <li> <p>painful diabetic neuropathy;</p> </li> <li> <p>peripheral polyneuropathy of other aetiologies, for example toxic (alcohol, drugs);</p> </li> <li> <p>phantom limb pain;</p> </li> <li> <p>postherpetic neuralgia;</p> </li> <li> <p>postoperative or traumatic peripheral nerve lesions;</p> </li> <li> <p>spinal cord injury;</p> </li> <li> <p>nerve plexus injury;</p> </li> <li> <p>trigeminal neuralgia.</p> </li> </ol> </p> <p>Where included studies had participants with more than one type of neuropathic pain, we analysed results according to the primary condition. Studies had to state explicitly that they included people with neuropathic pain (by title). We excluded studies that assessed pain in people with neurological diseases without specifying that the pain assessed was of neuropathic nature. We excluded studies with fibromyalgia because the nature of fibromyalgia (neuropathic or not) is under debate (<a href="./references#CD012182-bbs2-0049" title='ClauwD . What is the meaning of "small fiber neuropathy" in fibromyalgia?Pain2015;156(11):2115-6.'>Clauw 2015</a>); cannabis‐based medicines in fibromyalgia are the subject of another Cochrane Review (<a href="./references#CD012182-bbs2-0082" title="WalittB , KloseP , FitzcharlesMA , HäuserW . Cannabinoids for fibromyalgia. Cochrane Database of Systematic Reviews2016, Issue 7. Art. No: CD011694. [DOI: 10.1002/14651858.CD011694]">Häuser 2016</a>). We excluded studies with 'mixed pain' (<a href="./references#CD012182-bbs2-0040" title="BaronR , BinderA . How neuropathic is sciatica? The mixed pain concept [Wie neuropathisch ist die lumboischialgie? Das gemischte schmerz konzept]. Orthopäde2004;33:568-75.">Baron 2004</a>), because the concept is neither internationally accepted nor sufficiently validated and the focus of this review is only neuropathic pain. </p> </section> <section id="CD012182-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Cannabis‐based medicines, either herbal cannabis (hashish, marihuana), plant‐based cannabinoids (dronabinol: nabiximols), or pharmacological (synthetic) cannabinoids (e.g. levonantradol, nabilone), at any dose, by any route, administered for the relief of neuropathic pain and compared to placebo or any active comparator. We did not include studies with drugs under development that manipulate the endocannabinoid system by inhibiting enzymes that hydrolyse endocannabninoids and thereby boost the levels of the endogenous molecules (e.g. blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH)) (<a href="./references#CD012182-bbs2-0096" title="LongJZ , NomuraDK , VannRE , WalentinyDM , BookerL , JinX , et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Science of the United States of America2009;106:20,270-5.">Long 2009</a>). </p> </section> <section id="CD012182-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The standards used to assess evidence in chronic pain trials have changed substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of eight to 12 weeks' duration or longer. These standards are set out in the <i>PaPaS Author and Referee Guidance</i> for pain studies of Cochrane Pain, Palliative and Supportive Care (<a href="./references#CD012182-bbs2-0050" title="Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. papas.cochrane.org/papas-documents (accessed 5 June 2015).">Cochrane PaPaS 2012</a>). This Cochrane Review assessed evidence using methods that make both statistical and clinical sense, and will use criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD012182-bbs2-0106" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). </p> <p>We anticipated that studies would use a variety of outcome measures, with most studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS) for pain intensity or pain relief, or both). We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD012182-bbs2-0059" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]">Dworkin 2008</a>). </p> <section id="CD012182-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012182-list-0002"> <li> <p>Participant‐reported pain relief of 50% or greater. We preferred composite neuropathic pain scores over single‐scale generic pain scores if both measures were used by studies; </p> </li> <li> <p>PGIC (Patient Global Impression of Change) much or very much improved;</p> </li> <li> <p>Withdrawals due to adverse events (tolerability);</p> </li> <li> <p>Serious adverse events (safety). Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the person, or may require an intervention to prevent one of the above characteristics/consequences. </p> </li> </ol> </p> </section> <section id="CD012182-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012182-list-0003"> <li> <p>Participant‐reported pain relief of 30% or greater. We preferred composite neuropathic pain scores over single‐scale generic pain scores if both measures were used by studies; </p> </li> <li> <p>Mean pain intensity. We preferred composite neuropathic pain scores over single‐scale generic pain scores if both measures were used by studies; </p> </li> <li> <p>Health‐related quality of life;</p> </li> <li> <p>Sleep problems;</p> </li> <li> <p>Fatigue;</p> </li> <li> <p>Psychological distress;</p> </li> <li> <p>Withdrawals due to lack of efficacy;</p> </li> <li> <p>Any adverse event;</p> </li> <li> <p>Specific adverse events, particularly nervous system (e.g. dizziness, somnolence, headache) and psychiatric disorders (e.g. confusion state; paranoia, psychosis, substance dependence) according to the Medical Dictionary for Regulatory Activities (MedDRA) (<a href="./references#CD012182-bbs2-0085" title="International Council for Harmonisation. Medical Dictionary for Regulatory Activities Version 19.1. www.meddra.org/news-and-events/news/all-translations-meddra-version-191-are-now-available2016.">International Council for Harmonisation 2016</a>). </p> </li> </ol> </p> </section> </section> </section> <section id="CD012182-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012182-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases, without language restrictions:</p> <p> <ol id="CD012182-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (searched 7 November 2017); </p> </li> <li> <p>MEDLINE (via Ovid) (1946 to 7 November 2017);</p> </li> <li> <p>Embase (via Ovid) (1974 to 7 November 2017).</p> </li> </ol> </p> <p><a href="./appendices#CD012182-sec-0164">Appendix 2</a> shows the search strategies. </p> </section> <section id="CD012182-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any RCTs identified and review articles, and searched the following clinical trials databases: US National Institutes of Health clinical trial register (www.<a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>), European Union Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>), World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), and International Association for Cannabinoid Medicines (IACM) databank (<a href="http://www.cannabis-med.org/studies/study.php" target="_blank">www.cannabis-med.org/studies/study.php</a>) to identify additional published or unpublished data. We contacted trial investigators to request missing data. </p> </section> </section> <section id="CD012182-sec-0026"> <h3 class="title" id="CD012182-sec-0026">Data collection and analysis</h3> <p>We performed separate analyses according to particular neuropathic pain conditions. We combined different neuropathic pain conditions in analyses for exploratory purposes only. </p> <section id="CD012182-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (WH, FP) determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors (WH, FP) independently read these studies and reached agreement by discussion. We did not anonymise the studies before assessment. We created a PRISMA flow chart (<a href="./references#CD012182-bbs2-0102" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]">Moher 2009</a>). </p> </section> <section id="CD012182-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WH, FP) extracted data independently using a standard form and checked for agreement before entering data into Review Manager 5 (<a href="./references#CD012182-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). Two review authors (WH, MM) extracted independently data calculated by imputation. We included information about the pain condition and number of participants treated, study setting, inclusion and exclusion criteria, demographic and clinical characteristics of the study samples (age, gender, race, pain baseline), prior recreational cannabis use, drug and dosing regimen, co‐therapies allowed, rescue medication, study design (placebo or active control), study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event or serious adverse event). </p> </section> <section id="CD012182-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (WH, FP) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012182-bbs2-0077" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), and adapted from those used by Cochrane Musculoskeletal for recent reviews on drug therapy in fibromyalgia, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ol id="CD012182-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (i.e. any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (when the method used to generate the sequence was not clearly stated). We excluded studies at a high risk of bias that used a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when method was not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel/treatment providers (systematic performance bias). We assessed the methods used to blind participants and personnel/treatment providers from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (blinding of participants was not ensured, e.g. tablets different in form or taste). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that outcome assessors were blinded to the intervention or exposure status of participants); unclear risk of bias (study stated that the outcome assessors were blinded but did not provide an adequate description of how it was achieved); high risk of bias (outcome assessors knew the intervention or exposure status of participants). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% of participants did not complete the study or used 'baseline observation carried forward' (BOCF) analysis, or both); unclear risk of bias (used 'last observation carried forward' analysis); or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if an a priori study protocol was available and if all outcomes of the study protocol were reported in the publications of the study. There is low risk of reporting bias if the study protocol is available and all of the study's pre‐specified (primary and secondary) outcomes that are of interest in the review are reported in the pre‐specified way, or if the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that are pre‐specified (convincing text of this nature may be uncommon). There is a high risk of reporting bias if not all of the study's pre‐specified primary outcomes are reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that are not pre‐specified; one or more reported primary outcomes are not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study. There is unclear risk of bias if insufficient information is available to permit judgement of ‘Low risk’ or ‘High risk’. </p> </li> <li> <p>Group similarity at baseline (selection bias). We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. There is low risk of bias if groups are similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors. There is an unclear risk of bias if important prognostic clinical and demographic indicators are not reported. There is high risk of bias if groups are not similar at baseline for demographic factors, value of main outcome measure(s), and important prognostic factors. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ol> </p> <p>Two review authors (WH, FP) assessed the included studies using the Cochrane 'Risk of bias' tool. We defined studies with zero to two unclear or high risks of bias to be high‐quality studies, with three to five unclear or high risks of bias to be moderate‐quality studies, and with six to eight unclear or high risks of bias to be low‐quality studies (<a href="./references#CD012182-bbs2-0127" title="SchaefertR , WelschP , KloseP , SommerC , PetzkeF , HäuserW . Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration [Opioide bei chronischem arthroseschmerz. Systematische übersicht und metaanalyse der wirksamkeit, verträglichkeit und sicherheit in randomisierten, placebokontrollierten studien über mindestens 4 wochen]. Schmerz2015;29:47-59.">Schaefert 2015</a>). </p> </section> <section id="CD012182-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated numbers needed to treat for an additional beneficial outcome (NNTB) as the reciprocal of the absolute risk reduction (ARR; <a href="./references#CD012182-bbs2-0099" title="McQuayH , MooreR . An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]">McQuay 1998</a>). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. We used dichotomous data to calculate risk differences (RD) with 95% CIs using a fixed‐effect model unless we found significant statistical or clinical heterogeneity (see below). We set the threshold for a clinically relevant benefit or a clinically relevant harm for categorical variables by an NNTB or NNTH less than 10 (<a href="./references#CD012182-bbs2-0104" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]">Moore 2008</a>). </p> <p>We calculated standardised mean differences (SMD) with 95% CIs for continuous variables using a fixed‐effect model unless we found significant statistical or clinical heterogeneity. We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g value of 0.2 = small, 0.5 = medium, and 0.8 = large (<a href="./references#CD012182-bbs2-0051" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. Hillsdale: Lawrence Erlbaum Associates, 1988.">Cohen 1988</a>). We labelled a g value less than 0.2 to be a 'not substantial' effect size. We assumed a minimally important difference if the Hedges' g value was 0.2 or greater (<a href="./references#CD012182-bbs2-0063" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality of Life Research2014;23:1-4.">Fayers 2014</a>). </p> </section> <section id="CD012182-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. </p> <p>We included studies with a cross‐over design where separate data from the two periods were reported, data were presented that excluded a statistically significant carry‐over effect, or statistical adjustments were carried out in case of a significant carry‐over effect. </p> </section> <section id="CD012182-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post‐baseline assessment. </p> <p>Where means or standard deviations (SDs) were missing, we attempted to obtain these data through contacting trial authors. Where SDs were not available from trial authors, we calculated them from t values, P values, CIs, or standard errors, where reported by the studies (<a href="./references#CD012182-bbs2-0078" title="HigginsJPT , DeeksJJ , Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011b</a>). Where rates of pain relief of 30% and of 50% or greater were not reported or provided on request, we calculated them from means and SDs using a validated imputation method (<a href="./references#CD012182-bbs2-0067" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52.">Furukawa 2005</a>). </p> </section> <section id="CD012182-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity by combining studies that examined similar conditions. We assessed statistical heterogeneity visually (<a href="./references#CD012182-bbs2-0094" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107:224-33.">L'Abbé 1987</a>), and using the I<sup>2</sup> statistic (<a href="./references#CD012182-bbs2-0076" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). When the I<sup>2</sup> value was greater than 50%, we considered possible reasons for this. </p> </section> <section id="CD012182-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher; <a href="./references#CD012182-bbs2-0104" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]">Moore 2008</a>). </p> </section> <section id="CD012182-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We intended to use a fixed‐effect model for meta‐analysis. We used a random‐effects model using the inverse variance method in Review Manager 5 for meta‐analysis (<a href="./references#CD012182-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) because there was significant clinical heterogeneity due to the different types of neuropathic pain conditions included. </p> <section id="CD012182-sec-0036"> <h5 class="title">Quality of the evidence</h5> <p>Two review authors (WH, FP) independently rated the quality of the outcomes. We used the GRADE system to rank the quality of the evidence using the GRADEpro Guideline Development Tool software (<a href="./references#CD012182-bbs2-0069" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>), and the guidelines provided in Chapter 12.2 of the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012182-bbs2-0128" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Schünemann 2011</a>). </p> <p>The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence: </p> <p> <ol id="CD012182-list-0006"> <li> <p>high: we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> </li> <li> <p>very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> <p>We decreased the grade rating by one (‐ 1) or two (‐ 2) if we identified:</p> <p> <ol id="CD012182-list-0007"> <li> <p>serious (‐ 1) or very serious (‐ 2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐ 1);</p> </li> <li> <p>some (‐ 1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐ 1);</p> </li> <li> <p>high probability of reporting bias (‐ 1).</p> </li> </ol> </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012182-bbs2-0072" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66:151-7.">Guyatt 2013a</a>). For example, if there are so few data that the results are highly susceptible to the random play of chance, or if a study uses last observation carried forward (LOCF) imputation in circumstances where there are substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we planned to report the level of evidence as very low quality (<a href="./references#CD012182-bbs2-0073" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology2013;66:158-72.">Guyatt 2013b</a>). </p> <p>See also <a href="./appendices#CD012182-sec-0165">Appendix 3</a>: GRADE: criteria for assigning grade of evidence. </p> </section> <section id="CD012182-sec-0037"> <h5 class="title">'Summary of findings' table</h5> <p>We included one 'Summary of findings' table to present the main findings in a transparent and simple tabular format. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the outcomes. The 'Summary of findings' table includes the primary outcomes and the secondary outcomes of participant‐reported pain relief of 30% or greater, and nervous system disorders and psychiatric disorders as specific adverse events. </p> </section> </section> <section id="CD012182-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses according to individual neuropathic pain syndromes because placebo response rates for the same outcome can vary between conditions, as can the drug‐specific effects (<a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). We performed subgroup analyses (different cannabis‐based medicines; very short‐term (less than four weeks), short‐term (four to 12 weeks), intermediate‐term (13 to 26 weeks), and long‐term (more than 26 weeks) study duration) where there were at least two studies available. We post‐hoc decided to perform subgroup analyses of studies with and without publication in peer‐reviewed journals. We performed subgroup analyses if at least two studies for a subgroup were available. </p> </section> <section id="CD012182-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned no sensitivity analysis because the evidence base is known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012182-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012182-sec-0040"></div> <section id="CD012182-sec-0041"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD012182-sec-0177" title="">Characteristics of included studies</a>; <a href="./references#CD012182-sec-0178" title="">Characteristics of excluded studies</a>; <a href="./references#CD012182-sec-0179" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD012182-sec-0042"> <h4 class="title">Results of the search</h4> <p><a href="./appendices#CD012182-sec-0164">Appendix 2</a> shows the search strategies and hits retrieved for these databases. The searches (performed 7 November 2017) produced 1446 records after duplicates were removed. We identified 264 potentially relevant studies in CENTRAL, 949 in MEDLINE, 494 in Embase, three in the European Union Clinical Trials Register, 27 in the US National Institutes of Health clinical trials register, 116 in the WHO clinical trial register and 28 in the International Association for Cannabinoid Medicines (IACM) databank. After removing duplicates and reading the full reports, we included 16 studies involving 1750 participants into the qualitative and quantitative analysis (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a><a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>) (see <a href="#CD012182-fig-0001">Figure 1</a>). We excluded 15 studies. Of note, three studies from the database of the US National Institutes of Health have been not published in peer‐reviewed journals, and are awaiting classification. The results of three studies have not been published so far in the database of the US National Institutes of Health (<a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>). </p> <div class="figure" id="CD012182-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012182-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012182-sec-0043"> <h4 class="title">Included studies</h4> <section id="CD012182-sec-0044"> <h5 class="title">Characteristics of the studies</h5> <section id="CD012182-sec-0045"> <h6 class="title">Study design</h6> <p>Six studies used a cross‐over design (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), nine a parallel design (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>) and two an enriched enrolment randomised withdrawal (EERW) design (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>;<a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>). </p> </section> <section id="CD012182-sec-0046"> <h6 class="title">Study duration</h6> <p>Three studies were very short‐term studies (two to four weeks) (<a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), eight were short‐term studies (four to 12 weeks) (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>), and five were intermediate‐term studies (12 to 26 weeks) (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>). </p> </section> <section id="CD012182-sec-0047"> <h6 class="title">Study setting</h6> <p>Five studies were conducted in the UK (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>), three studies in Canada (<a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), three studies in multiple European countries (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>), and one study in multiple countries of different continents (<a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>), one study in USA (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>), one study in Romania (<a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>), one study in Germany (<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>) and one study in Denmark (<a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>). Nine studies were single centre (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>;<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), and seven were multicentre (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>). </p> </section> <section id="CD012182-sec-0048"> <h6 class="title">Sample sizes</h6> <p>The sample sizes ranged between 20 and 339.</p> </section> <section id="CD012182-sec-0049"> <h6 class="title">Study periods</h6> <p>Study period was between 2000 and 2010 in seven studies (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). The remaining studies did not report the study period. </p> </section> <section id="CD012182-sec-0050"> <h6 class="title">Study funding</h6> <p>Three studies were funded by public funds (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), one study reported that there was no external funding (<a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>), and the remaining studies were funded by the manufacturer of the drug. Four authors declared that they had no conflict of interest (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). Six studies did not report on conflicts of interest (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>). Six authors reported potential conflicts of interest by honoraria and/or funding received by the manufacturer of the drug studied (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>). </p> </section> </section> <section id="CD012182-sec-0051"> <h5 class="title">Characteristics of the participants</h5> <section id="CD012182-sec-0052"> <h6 class="title">Types of neuropathic pain</h6> <p>Five studies included participants with neuropathic pain associated with multiple sclerosis (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>), three studies with mixed peripheral pain of various aetiologies (<a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), three studies with diabetic polyneuropathy (<a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>), and one study with plexus injury (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>), one study with spinal cord injury (<a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>), one study with HIV‐neuropathy (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>), one study with chemotherapy‐induced polyneuropathy (<a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>), and one study with mixed central or peripheral pain of various aetiologies (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>). </p> </section> <section id="CD012182-sec-0053"> <h6 class="title">Demographics</h6> <p>The mean age of the participants ranged between 34 and 61 years. The youngest mean age was in the studies with medical cannabis (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). The percentage of men ranged between 17% and 100%. </p> </section> <section id="CD012182-sec-0054"> <h6 class="title">Inclusion criteria</h6> <p>Nine studies required a pain score of 4 or above on a zero to 10 scale at baseline for inclusion (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>). The remaining studies did not report on an inclusion criterion of a defined pain intensity. Five studies required for inclusion that the pain was refractory to previous analgesics without specifying the type and dosage of previous unsuccessful analgesic therapy (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). </p> </section> <section id="CD012182-sec-0055"> <h6 class="title">Exclusion criteria</h6> <p>All studies excluded people with major medical diseases (heart, liver, kidney, seizures). Ten studies mentioned explicitly that they excluded people with a history of substance abuse (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>). </p> </section> <section id="CD012182-sec-0056"> <h6 class="title">Previous experience of participants with herbal cannabis</h6> <p>Nine studies reported previous herbal cannabis experience of participants for medical and/or recreational use (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). The percentage of participants with previous herbal cannabis experience ranged from 7% to 91%. Of note, the rates of previous herbal cannabis experience were the highest in the two studies with inhaled cannabis, with 91% in <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a> and 81% in <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>. One study excluded people who had used marijuana in the month before study entry (<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>). </p> </section> </section> <section id="CD012182-sec-0057"> <h5 class="title">Characteristics of the treatment delivered</h5> <section id="CD012182-sec-0058"> <h6 class="title">Types of cannabis‐based medicines</h6> <p>All studies used THC/CBD oromucosal spray except two studies that used oral synthetic THC (nabilone) (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>), two studies that used plant‐based THC (dronabinol) (<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a><a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a> and two studies that used inhaled (by pipe or cigarette) herbal cannabis (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). All studies compared to placebo except one study that compared to dihydrocodeine (DHC) (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>). </p> </section> <section id="CD012182-sec-0059"> <h6 class="title">Rescue and Co‐medication</h6> <p>Two studies (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>) did not allow rescue medication. Five studies used paracetamol (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>) and one study tramadol (<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>). The remaining studies did not report details on rescue medication (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). Four studies did not report if co‐medications were allowed (<a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>). The remaining studies allowed stable dosage of analgesic co‐medications. </p> </section> </section> </section> <section id="CD012182-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 studies for the following reasons: five studies because no definite statement was given that the pain was of neuropathic nature (<a href="./references#CD012182-bbs2-0018" title="Corey-BloomJ , WolfsonT , GamstA , JinS , MarcotteTD , BentleyH , et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Canadian Medical Association Journal2012;184:1143-50. ">Corey‐Bloom 2012</a>; <a href="./references#CD012182-bbs2-0021" title="NovotnaA , MaresJ , RatcliffeS , NovakovaI , VachovaM , ZapletalovaO , et al. Arandomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology2011;18:1122-31. ">Novotna 2011</a>; <a href="./references#CD012182-bbs2-0025" title="WadeDT , MakelaP , RobsonP , HouseH , BatemanC . Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis2004;10:434-41. ">Wade 2004</a>; <a href="./references#CD012182-bbs2-0029" title="WisselJ , HaydnT , MüllerJ , BrenneisC , BergerT , BergerT . Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. Journal of Neurology2006;253:1337-41. ">Wissel 2006</a>; <a href="./references#CD012182-bbs2-0031" title="ZajicekJP , HobartJC , SladeA , BarnesD , MattisonPG , MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of Neurology, Neurosurgery and Psychiatry2012;83:1125-32. ">Zajicek 2012</a>); five studies because the study duration was less than two weeks (<a href="./references#CD012182-bbs2-0017" title="AbramsDI , JayCA , ShadeSB , VizosoH , RedaH , PressS , et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology2007;68:515-21. ">Abrams 2007</a>; <a href="./references#CD012182-bbs2-0019" title="KarstM , SalimK , BursteinS , ConradI , HoyL , SchneiderU . Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA2003;290:1757-62. ">Karst 2003</a>; <a href="./references#CD012182-bbs2-0026" title="WallaceMS , MarcotteTD , UmlaufA , GouauxB , AtkinsonJH . Efficacy of inhaled cannabis on painful diabetic neuropathy. Journal of Pain2015;16:616-27. ">Wallace 2015</a>; <a href="./references#CD012182-bbs2-0028" title="WilseyB , MarcotteT , DeutschR , GouauxB , SakaiS , GouauxB , et al. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain2013;14:136-48. ">Wilsey 2013</a>; <a href="./references#CD012182-bbs2-0027" title="WilseyB , MarcotteT , TsodikovA , MillmanJ , BentleyH , DonagheH . A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain2008;9:506-21. ">Wilsey 2008</a>). one because the reports of the outcomes of efficacy did not meet the predefined inclusion criteria for efficacy (<a href="./references#CD012182-bbs2-0030" title="ZajicekJ , FoxP , SandersH , WrightD , VickeryJ , NunnA , et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet2003;362:1517-26. ">Zajicek 2003</a>), two studies because there were fewer than 10 participants per treatment arm (<a href="./references#CD012182-bbs2-0022" title="RintalaDH , FiessRN , TanG , HolmesSA , BruelBM . Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. American Journal of Physical Medicine &amp; Rehabilitation2010;89:840-8. ">Rintala 2010</a>; <a href="./references#CD012182-bbs2-0023" title="TurcotteD , DoupeM , TorabiM , GomoriA , EthansK , EsfahaniF , et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Medicine2015;16:149-59. ">Turcotte 2015</a>), and one study each because participants with non‐neuropathic pain were included (<a href="./references#CD012182-bbs2-0020" title="NotcuttW , PriceM , MillerR , NewportS , PhillipsC , SimmonsS , et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia2004;59:440-52. ">Notcutt 2011</a>) and participants without pain were included (<a href="./references#CD012182-bbs2-0024" title="WadeDT , RobsonP , HouseH , MakelaP , AramJ . A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation2003;17:21-9. ">Wade 2003</a>). </p> </section> <section id="CD012182-sec-0061"> <h4 class="title">Studies awaiting assessment</h4> <p>We found three studies with unpublished results or unknown status of which we received no information from the contacted authors. All three studies were conducted with nabilone by Canadian universities (<a href="./references#CD012182-bbs2-0032" title="NCT00699634. Nabilone for the treatment of phantom limb pain. clinicaltrials.gov/ct2/show/NCT00699634?term=NCT00699634&amp;rank=1 (first posted 18 June 18). ">NCT00699634</a>; <a href="./references#CD012182-bbs2-0033" title="NCT01035281. Efficacy study of nabilone in the treatment of diabetic peripheral neuropathic pain. clinicaltrials.gov/ct2/show/NCT01035281?term=NCT01035281&amp;rank=1 (first posted 18 December 2009). ">NCT01035281</a>; <a href="./references#CD012182-bbs2-0034" title="NCT01222468. Effect of cannabinoids on spasticity and neuropathic pain in spinal cord injured persons. clinicaltrials.gov/ct2/show/NCT01222468?term=NCT01222468&amp;rank=1 (first posted 18 October 2010). ">NCT01222468</a>). One of these studies was sponsored by the manufacturer of the drug (<a href="./references#CD012182-bbs2-0032" title="NCT00699634. Nabilone for the treatment of phantom limb pain. clinicaltrials.gov/ct2/show/NCT00699634?term=NCT00699634&amp;rank=1 (first posted 18 June 18). ">NCT00699634</a>); the remaining two studies were funded by the university (<a href="./references#CD012182-bbs2-0033" title="NCT01035281. Efficacy study of nabilone in the treatment of diabetic peripheral neuropathic pain. clinicaltrials.gov/ct2/show/NCT01035281?term=NCT01035281&amp;rank=1 (first posted 18 December 2009). ">NCT01035281</a>; <a href="./references#CD012182-bbs2-0034" title="NCT01222468. Effect of cannabinoids on spasticity and neuropathic pain in spinal cord injured persons. clinicaltrials.gov/ct2/show/NCT01222468?term=NCT01222468&amp;rank=1 (first posted 18 October 2010). ">NCT01222468</a>). </p> </section> </section> <section id="CD012182-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of most domains was unclear in all studies: see <a href="#CD012182-fig-0002">Figure 2</a> and <a href="#CD012182-fig-0003">Figure 3</a> for a ’Risk of bias’ summary and graph and <a href="./references#CD012182-sec-0177" title="">Characteristics of included studies</a> for detailed information regarding 'Risk of bias' assessments of each study. The overall study quality according to the predefined criteria of the Cochrane 'Risk of bias' tool was low quality in two studies (<a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>), moderate quality in 12 studies (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>) and high quality in two studies (<a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>). </p> <div class="figure" id="CD012182-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012182-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012182-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012182-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD012182-sec-0063"> <h4 class="title">Allocation</h4> <section id="CD012182-sec-0064"> <h5 class="title">Random sequence generation</h5> <p>Random sequence generation was adequately described and therefore of low risk of bias in all studies except <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>, which did not adequately describe it (unclear risk of bias). </p> </section> <section id="CD012182-sec-0065"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was adequately described and therefore of low risk of bias in all studies except <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>, which did not adequately describe it (unclear risk of bias). </p> </section> </section> <section id="CD012182-sec-0066"> <h4 class="title">Blinding</h4> <section id="CD012182-sec-0067"> <h5 class="title">Blinding of participants and personnel</h5> <p>Blinding of participants and personnel was adequately described and therefore of low risk of bias in all studies except <a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>, which did not adequately describe it (unclear risk of bias). </p> </section> <section id="CD012182-sec-0068"> <h5 class="title">Blinding of outcome assessor</h5> <p>Blinding of outcome assessment for adverse events was only adequately described by <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a> and <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>. The remaining studies did not adequately describe it (unclear risk of bias). </p> </section> </section> <section id="CD012182-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Only one study performed intention‐to‐treat (ITT) analysis by baseline observation carried forward (BOCF) method (<a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>). Three studies performed completer analysis (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>) (high risk of bias). The remaining studies performed ITT by last observation carried forward (LOCF) method and were therefore of unclear risk of bias. </p> </section> <section id="CD012182-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Two studies were of high risk of bias because they did not report all predefined outcomes (<a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>). Four studies did not report on a study protocol and were therefore of unclear risk of bias (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>). The remaining studies reported the outcomes as defined in a study protocol. </p> </section> <section id="CD012182-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <section id="CD012182-sec-0072"> <h5 class="title">Group similarity at baseline</h5> <p>All studies had a low risk of bias because there were no significant differences in demographic and clinical variables at baseline except one study with a high risk of bias (<a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>). </p> </section> <section id="CD012182-sec-0073"> <h5 class="title">Sample size</h5> <p>Sample size was of unclear risk of bias in seven studies (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>; <a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0006" title="NCT 00710424. A study of Sativex® for pain relief due to diabetic neuropathy. clinicaltrials.gov/ct2/results?term=NCT00710424+&amp;Search=Search (first Posted 4 July 2008). ">NCT00710424</a>; <a href="./references#CD012182-bbs2-0008" title="NCT 01606202. A study of cannabis based medicine extracts and placebo in patients with pain due to spinal cord injury. clinicaltrials.gov/ct2/results?term= NCT 01606202&amp;Search=Search (first posted 25 May 2012). ">NCT01606202</a>; <a href="./references#CD012182-bbs2-0009" title="NurmikkoTJ , SerpellMG , HoggartB , ToomeyPJ , MorlionBJ , HainesD . Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain2007;133:210-20. ">Nurmikko 2007</a>; <a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>; <a href="./references#CD012182-bbs2-0013" title="SerpellM , RatcliffeS , HovorkaJ , SchofieldM , TaylorL , LauderH , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain2014;18:999-1012. ">Serpell 2014</a>), and of high risk of bias in nine studies (<a href="./references#CD012182-bbs2-0001" title="BermanJS , SymondsC , BirchR . Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain2004;112:299-306. ">Bermann 2004</a>; <a href="./references#CD012182-bbs2-0002" title="EllisRJ , ToperoffW , VaidaF , Van den BrandeG , GonzalesJ , GouauxB , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology2009;34(3):672-80. ">Ellis 2009</a>; <a href="./references#CD012182-bbs2-0005" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of Pain and Symptom Management2014;47:166-73. ">Lynch 2014</a>; <a href="./references#CD012182-bbs2-0007" title="NCT01606176. A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin. clinicaltrials.gov/ct2/results?cond=&amp;term=NCT01606176&amp;cntry1=&amp;state1=&amp;recrs= (first posted 25 May 2012). ">NCT01606176</a>; <a href="./references#CD012182-bbs2-0010" title="RogDJ , NurmikkoTJ , FriedeT , YoungCA . Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology2005;65:812-9. ">Rog 2005</a>; <a href="./references#CD012182-bbs2-0012" title="SelvarajahD , GandhiR , EmeryCJ , TesfayeS . Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care2010;33:128-30. ">Selvarajah 2010</a>; <a href="./references#CD012182-bbs2-0014" title="SvendsenKB , JensenTS , BachFW . Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ2004;329:253. ">Svendsen 2004</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>; <a href="./references#CD012182-bbs2-0016" title="WareMA , WangT , ShapiroS , RobinsonA , DucruetT , HuynhT , et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Canadian Medical Association Journal2010;184:E694-701. ">Ware 2010</a>). </p> </section> </section> </section> <section id="CD012182-sec-0074"> <h3 class="title" id="CD012182-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD012182-tbl-0001"><b>Summary of findings 1</b> Cannabis‐based medicines compared with placebo for chronic neuropathic pain</a> </p> <section id="CD012182-sec-0075"> <h4 class="title">All cannabis‐based medicines versus placebo ‐ studies with a cross‐over and parallel design </h4> <p>See <a href="./full#CD012182-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012182-sec-0076"> <h5 class="title">Primary outcomes</h5> <p>The quailty of evidence was downgraded by one level due to indirectness (people with current or historical substance abuse, or both, and major medical diseases excluded) for all outcomes. </p> <section id="CD012182-sec-0077"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>We analysed eight studies with 1001 participants. One hundred and 10 of 526 (20.9%) participants in the cannabis‐based medicines and 82 of 475 (17.3%) participants in the placebo group reported pain relief of 50% or greater (risk difference (RD) 0.05, 95% CI 0.00 to 0.09); P value 0.04; I² = 29%). NNTB was 20 (11 to 100). According to the predefined categories, there was no clinically relevant benefit of cannabis‐based medicines (see <a href="./references#CD012182-fig-0004" title="">Analysis 1.1</a>). The quality of evidence was low, downgraded due to indirectness and imprecision (CI included zero). </p> </section> <section id="CD012182-sec-0078"> <h6 class="title">Patient Global Impression of Change much or very much improved</h6> <p>We analysed six studies with 1092 participants. One hundred and fifty‐six of 548 (28.4%) participants in the cannabis‐based medicines and 112 of 544 (22.1%) participants in the placebo group reported to be much or very much improved (RD 0.09 (95% CI 0.01 to 0.17; P value 0.02; I² = 58%). The NNTB was 11 (6 to 100). According to the predefined categories, there was no clinically relevant benefit of cannabis‐based medicines (see <a href="./references#CD012182-fig-0005" title="">Analysis 1.2</a>). The quality of evidence was very low, downgraded due to indirectness, inconsistency (I²&gt;50%) and publication bias (all studies funded by the manufacturer of the drug). </p> </section> <section id="CD012182-sec-0079"> <h6 class="title">Withdrawals due to adverse events</h6> <p>We analysed 13 studies with 1848 participants. One hundred and three of 989 (10.4%) participants in the cannabis‐based medicines and 40 of 859 (4.7%) participants in the placebo group withdrew due to adverse events (RD 0.04, 95% CI 0.02 to 0.07; P value 0.0009; I² = 25%). The NNTH was 25 (16 to 50). According to the predefined categories there was no clinically relevant harm by cannabis‐based medicines (see <a href="./references#CD012182-fig-0006" title="">Analysis 1.3</a>). The quality of evidence was moderate, downgraded due to indirectness. </p> </section> <section id="CD012182-sec-0080"> <h6 class="title">Serious adverse events</h6> <p>We analysed 13 studies with 1876 participants. Sity‐six of 989 (6.7%) participants in the cannabis‐based medicines and 46 of 887 (5.2%) participants in the placebo group reported serious adverse events (RD 0.01, 95% CI ‐0.01 to 0.03; P value 0.29; I² = 0%) (see <a href="./references#CD012182-fig-0007" title="">Analysis 1.4</a>). The quality of evidence was low, downgraded due to indirectness and imprecision (CI included zero; low number of events). </p> </section> </section> <section id="CD012182-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD012182-sec-0082"> <h6 class="title">Participant‐reported pain relief of 30% or greater</h6> <p>We analysed 10 studies with 1586 participants. Three hundred and twenty‐three of 819 (39.4%) participants in the cannabis‐based medicines and 251 of 767 (32.7%) participants in the placebo group reported pain relief of 30% or greater (RD 0.09, 95% CI 0.03 to 0.15; P value 0.004; I² = 34%). NNTB was 11 (7 to 33). According to the predefined categories, there was no clinically relevant benefit by cannabis‐based medicines (see <a href="./references#CD012182-fig-0008" title="">Analysis 1.5</a>). The quality of evidence was moderate, downgraded due to indirectness. </p> </section> <section id="CD012182-sec-0083"> <h6 class="title">Mean pain intensity</h6> <p>We analysed 14 studies with 1837 participants. Cannabis‐based medicines were superior to placebo in the reduction of mean pain intensity (standardised mean difference (SMD) ‐0.35, 95% CI ‐0.60 to ‐0.09; P value 0.008; I² = 84%). According to Cohen’s categories, there was a small effect size indicating a minimal clinically important improvement (see <a href="./references#CD012182-fig-0009" title="">Analysis 1.6</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> <section id="CD012182-sec-0084"> <h6 class="title">Health‐related quality of life</h6> <p>We analysed nine studies with 1284 participants. Cannabis‐based medicines were not superior to placebo in the improvement of health‐related quality of life (HRQoL) (SMD 0.02, 95% CI ‐0.10 to 0.13; P value 0.79; I² = 0%) (see <a href="./references#CD012182-fig-0010" title="">Analysis 1.7</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (CI included zero). </p> </section> <section id="CD012182-sec-0085"> <h6 class="title">Sleep problems</h6> <p>We analysed eight studies with 1386 participants. Cannabis‐based medicines were superior to placebo in the reduction of sleep problems (SMD ‐0.47, 95% CI ‐0.90 to ‐0.04; P value 0.03; I² = 92%). According to Cohen’s categories, there was a small effect size indicating a minimal clinically important improvement (see <a href="./references#CD012182-fig-0011" title="">Analysis 1.8</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> <section id="CD012182-sec-0086"> <h6 class="title">Fatigue</h6> <p>The analysis was not possible because fatigue was assessed only by one study (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>). </p> </section> <section id="CD012182-sec-0087"> <h6 class="title">Psychological distress</h6> <p>We analysed seven studies with 779 participants. Cannabis‐based medicines were statistically significantly superior to placebo in the reduction of psychological distress (SMD ‐0.32, 95% CI ‐0.61 to ‐0.02; P value 0.04; I² = 66%). According to Cohen’s categories, there was a small effect size indicating a minimal clinically important improvement (see <a href="./references#CD012182-fig-0012" title="">Analysis 1.9</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> <section id="CD012182-sec-0088"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p>We analysed nine studies with 1576 participants. There was no difference in the frequency of withdrawals due to lack of efficacy between cannabis‐based medicines and placebo. Twenty‐two of 818 (2.7%) participants in the cannabis‐based medicines and 31 of 758 (4.1%) participants in the placebo group withdrew due to lack of efficacy (RD ‐0.00, 95% CI ‐0.02 to 0.01; P value 0.79; I² = 0%) (see <a href="./references#CD012182-fig-0013" title="">Analysis 1.10</a>). The quality of evidence was low, downgraded due to indirectness and imprecision (CI included zero). </p> </section> <section id="CD012182-sec-0089"> <h6 class="title">Any adverse event</h6> <p>We analysed seven studies with 1356 participants. Five hundred and sixty‐two of 684 (80.2%) participants in the cannabis‐based medicines and 441 of 672 (65.6%) participants in the placebo group reported adverse events (RD 0.19, 95% CI 0.12 to 0.27; P value &lt; 0.0001; I² = 64%). NNTH was 5 (4 to 8). According to the predefined categories, there was a clinically relevant harm by cannabis‐based medicines (see <a href="./references#CD012182-fig-0014" title="">Analysis 1.11</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> <section id="CD012182-sec-0090"> <h6 class="title">Specific adverse events</h6> <section id="CD012182-sec-0091"> <p><b>Nervous system disorders</b></p> <p>We analysed nine studies with 1304 participants. Four hundred and fourteen of 677 (61.1%) participants in the cannabis‐based medicines and 180 of 627 (28.7%) participants in the placebo group reported adverse events of the nervous system (RD 0.38, 95% CI 0.18 to 0.58; P value 0.0003; I² = 94%). NNTH was 3 (2 to 6). According to the predefined categories, there was a clinically relevant harm by cannabis‐based medicines (see <a href="./references#CD012182-fig-0015" title="">Analysis 1.12</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> <section id="CD012182-sec-0092"> <p><b>Psychiatric disorders</b></p> <p>We analysed nine studies with 1314 participants. One hundred and twelve of 677 (16.5%) participants in the cannabis‐based medicines and 31 of 637 (4.9%) participants in the placebo group reported psychiatric adverse events (RD 0.10, 95% CI 0.06 to 0.15; P value &lt; 0.0001; I² = 54%). NNTH was 10 (7 to 16). According to the predefined categories, there was no clinically relevant harm by cannabis‐based medicines (see <a href="./references#CD012182-fig-0016" title="">Analysis 1.13</a>). The quality of evidence was low, downgraded due to indirectness and inconsistency (I²&gt;50%). </p> </section> </section> </section> </section> <section id="CD012182-sec-0093"> <h4 class="title">Cannabis‐based medicines versus placebo ‐ studies with an enriched enrolment randomised withdrawal design (results of double‐blind phase) </h4> <p>We present a qualitative analysis of the study results (<a href="./references#CD012182-bbs2-0004" title="LangfordRM , MaresJ , NovotnaA , VachovaM , NovakovaI , NotcuttW , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of Neurology2013;260:984-97. ">Langford 2013</a>; <a href="./references#CD012182-bbs2-0015" title="TothC , MawaniS , BradyS , ChanC , LiuC , MehinaE , et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain2012;153:2073-82. ">Toth 2012</a>) because the data were not suited for quantitative analysis. The quality of evidence for each outcome was very low, downgraded because of indirectness (people with current or historical substance abuse, or both, and major medical diseases excluded), imprecision (low number of events) and publication bias (all studies funded by manufacturer of the drug). </p> <section id="CD012182-sec-0094"> <h5 class="title">Primary outcomes</h5> <section id="CD012182-sec-0095"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>We analysed one study with 26 participants. There was no difference between nabilone and placebo in the number of participants with a 50% pain relief or greater (31% versus 8%; P value 0.12). </p> <p>We analysed one study with 42 participants. There was a difference between THC/CBD and placebo in the number of participants with a treatment failure (24% versus 57%; P value 0.04). </p> </section> <section id="CD012182-sec-0096"> <h6 class="title">Patient Global Impression of Change much or very much improved</h6> <p>We analysed one study with 26 participants. Six of 13 participants in the nabilone and one of 13 participants in the placebo group reported to be much or very much improved (P value 0.04). </p> </section> <section id="CD012182-sec-0097"> <h6 class="title">Withdrawals due to adverse events</h6> <p>We analysed two studies with 68 participants. There was no difference between cannabis‐based medicines and placebo. None of the 21 participants dropped out of the THC/CBD spray group and one of 21 dropped out of the placebo group. None dropped out in the nabilone (13 participants) or placebo (13 participants) groups. </p> </section> <section id="CD012182-sec-0098"> <h6 class="title">Serious adverse events</h6> <p>We analysed two studies with 68 participants. There was no difference between cannabis‐based medicines and placebo. Three of 21 participants experienced a serious adverse event in the THC/CBD spray and one of 21 in the placebo group. None experienced a serious adverse event in the nabilone (13 participants) or placebo (13 participants) group. </p> </section> </section> <section id="CD012182-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD012182-sec-0100"> <h6 class="title">Participant‐reported pain relief of 30% or greater</h6> <p>We analysed one study with 26 participants. There was a difference between nabilone and placebo in the number of participants with pain relief of 30% or greater (85% versus 38%; P value 0.006). </p> <p><b>Mean pain intensity</b> </p> <p>We analysed two studies with 68 participants. The estimated treatment difference between THC/CBD spray and placebo was ‐0.79 (P value 0.03). The average pain intensity was 3.5 ± 1.3 in the nabilone and 5.4 ± 1.7 in the placebo group (P value 0.005) (higher scores indicate more pain). </p> <p><b>Health‐related quality of life</b> </p> <p>We analysed two studies with 68 participants. The estimated treatment difference between THC/CBD spray and placebo was 1.94 (P value 0.18) in one study. The HRQoL score was 0.74 ± 0.03 in the nabilone and 0.60 ± 0.8 in the placebo group (P value &lt; 0.05) in one study (higher scores indicating a better HRQoL). </p> <p><b>Sleep problems</b> </p> <p>We analysed two studies with 68 participants. The estimated treatment difference between THC/CBD spray and placebo was ‐0.99 (P value 0.02). The sleep problems score was 27.1 ± 2.1 in the nabilone and 33.0 ± 2.6 in the placebo group (P value &lt; 0.05) (higher scores indicate more sleep problems). </p> </section> <section id="CD012182-sec-0101"> <h6 class="title">Fatigue</h6> <p>Neither of these studies assessed this outcome.</p> <p><b>Psychological distress</b> </p> <p>We analysed one study with 42 participants. The estimated treatment difference between THC/CBD spray and placebo was ‐0.56 (P value 0.73). </p> <p><b>Withdrawals due to lack of efficacy</b> </p> <p>We analysed one study with 42 participants. None of the participants in the THC/CBD study dropped out due to lack of efficacy. </p> <p><b>Any adverse event</b> </p> <p>We analysed two studies with 68 participants. Ten per cent of participants with THC/CBD spray and 24% of participants with placebo reported an adverse event. Fifty‐four per cent of the participants receiving nabilone and 46% of the participants receiving placebo reported at least one adverse event (P value 1.0). </p> </section> <section id="CD012182-sec-0102"> <h6 class="title">Specific adverse events</h6> <section id="CD012182-sec-0103"> <p><b>Nervous system disorders</b></p> <p>We analysed one study with 42 participants. None of the participants in the THC/CBD group reported adverse events of the nervous system. </p> </section> <section id="CD012182-sec-0104"> <p><b>Psychiatric disorders</b></p> <p>We analysed one study with 42 participants. Five per cent of participants in both groups reported a psychiatric adverse event. </p> </section> </section> </section> </section> <section id="CD012182-sec-0105"> <h4 class="title">Cannabis‐based medicines versus any active other drug</h4> <p>Only one study compared nabilone with dihydrocodeine (DHC) in 73 participants (<a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a>). We therefore present a qualitative analysis of the study results. The quality of evidence for each outcome was very low, downgraded because of indirectness (people with current or historical substance abuse, and major medical diseases excluded), imprecision (low number of events) and publication bias (all studies funded by manufacturer of the drug). </p> <section id="CD012182-sec-0106"> <h5 class="title">Primary outcomes</h5> <section id="CD012182-sec-0107"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p><a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a> assessed this outcome, however the study authors reported only the mean pain intensity. </p> </section> <section id="CD012182-sec-0108"> <h6 class="title">Patient Global Impression of Change much or very much improved</h6> <p><a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a> did not assess this outcome. </p> </section> <section id="CD012182-sec-0109"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There was no difference between nabilone and DHC. Four of 96 participants dropped out in the nabilone group and 8/96 in the DHC group (P value 0.23). </p> <p><b>Serious adverse events</b> </p> <p>No major adverse events occurred when participants took either drug.</p> </section> </section> <section id="CD012182-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD012182-sec-0111"> <h6 class="title">Participant‐reported pain relief of 30% or greater</h6> <p><a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a> assessed this outcome, however the study authors reported only the mean pain intensity. </p> </section> <section id="CD012182-sec-0112"> <h6 class="title">Mean pain intensity</h6> <p>There was no difference between nabilone (59.93 ± 24.42) and DHC (58.58 ± 24.08) (P value not reported). </p> </section> <section id="CD012182-sec-0113"> <h6 class="title">Health‐related quality of life</h6> <p>There was no difference between nabilone and DHC with a treatment difference of 8.9 (P value 0.48). </p> </section> <section id="CD012182-sec-0114"> <h6 class="title">Sleep problems</h6> <p>There was no difference between nabilone and DHC with a treatment difference of 0.2 (P value 0.28). </p> </section> <section id="CD012182-sec-0115"> <h6 class="title">Fatigue</h6> <p><a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a> did not assess this outcome. </p> </section> <section id="CD012182-sec-0116"> <h6 class="title">Psychological distress</h6> <p>There was no difference between nabilone and DHC with a treatment difference of 2.5 (P value 0.35). </p> </section> <section id="CD012182-sec-0117"> <h6 class="title">Withdrawals due to lack of efficacy</h6> <p><a href="./references#CD012182-bbs2-0003" title="FrankB , SerpellMG , HughesJ , MatthewsJN , KapurD . Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ2008;336:199-201. ">Frank 2008</a> did not assess this outcome. </p> </section> <section id="CD012182-sec-0118"> <h6 class="title">Any adverse event</h6> <p>There were 334 adverse events reported in the nabilone and 305 in the DHC group (no difference). </p> </section> <section id="CD012182-sec-0119"> <h6 class="title">Specific adverse events</h6> <section id="CD012182-sec-0120"> <p><b>Nervous system disorders</b></p> <p>This outcome was not assessed.</p> </section> <section id="CD012182-sec-0121"> <p><b>Psychiatric disorders</b></p> <p>This outcome was not assessed.</p> </section> </section> </section> </section> <section id="CD012182-sec-0122"> <h4 class="title">Assessment of publication bias</h4> <p>The planned assessment of publication bias was not possible because the NNTB of all cannabis‐based medicines pooled together versus placebo for all dichotomous primary and secondary outcomes surpassed the pre‐set level of an NNTB of 10 or less. </p> </section> <section id="CD012182-sec-0123"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We post‐hoc decided to restrict subgroup analyses to the outcomes pain relief of 50% or greater, PGIC (Patient Global Impression of Change) much or very much improved, withdrawals due to adverse events, serious adverse events and mean pain intensity. A subgroup analysis was only performed with at least two studies available. </p> <section id="CD012182-sec-0124"> <h5 class="title">Different types of neuropathic pain syndromes</h5> <p>We excluded studies with mixed samples of central and/or peripheral neuropathic pain from subgroup analysis because we wanted to assess the effects of cannabis‐based medicines on distinctive neuropathic pain syndromes. We found no subgroup difference between different types of neuropathic pain syndromes in the outcomes pain relief of 50% or greater (P value 0.20), withdrawals due to adverse events (P value 0.13), serious adverse events (P value 0.97), and mean pain intensity (P value 0.46). There was a subgroup difference between different types of neuropathic pain syndromes in the outcome PGIC (P value 0.02). </p> </section> <section id="CD012182-sec-0125"> <h5 class="title">Different types of cannabis‐based medicines</h5> <section id="CD012182-sec-0126"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>THC/CBD oromucosal spray was not different to placebo. RD was 0.05 (95% CI ‐0.00 to 0.11) (P value 0.07) (seven studies with 737 participants. Dronabinol (two studies with 264 participants) was not different to placebo. RD was 0.05 (95% CI ‐0.05 to 0.15) (P value 0.31) This outcome could not be analysed for herbal cannabis. </p> <p><b>Patient Global Impression of Change much or very much improved</b> </p> <p>THC/CBD oromucosal spray (six studies with 1092 participants) was superior to placebo. RD was 0.09 (95% CI 0.01 to 0.17) (P value 0.02). The trials with dronabinol and herbal cannabis did not report this outcome. </p> </section> <section id="CD012182-sec-0127"> <h6 class="title">Withdrawals due to adverse events</h6> <p>THC/CBD oromucosal spray (nine studies with 1408 participants) was superior to placebo. RD was 0.05 (95% CI 0.01 to 0.08) (P value 0.007). Dronabinol (two studies with 264 participants) was not different to placebo. RD was 0.05 (95% CI ‐0.04 to 0.13) (P value 0.27). Herbal cannabis (two studies with 152 participants) was not different to placebo. RD was 0.00 (95% CI ‐0.08 to 0.08) (P value 0.71). </p> </section> <section id="CD012182-sec-0128"> <h6 class="title">Serious adverse events</h6> <p>THC/CBD oromucosal spray (eight studies with 1436 participants) was not different to placebo. RD was 0.01 (95% CI ‐0.01 to 0.02) (P value 0.52). Dronabinol (two studies with 264 participants) was not different to placebo. RD was 0.04 (95% CI ‐0.02 to 0.11) (P value 0.16). Herbal cannabis (two studies with 152 participants) was not different to placebo. RD was 0.01 (95% CI ‐0.05 to 0.06) (P value 0.74). </p> </section> <section id="CD012182-sec-0129"> <h6 class="title">Mean pain intensity</h6> <p>THC/CBD oromucosal spray (nine studies with 1433 participants) was superior to placebo. SMD was ‐0.40 (95% CI ‐0.75 to ‐0.05) (P value 0.03). Dronabinol (two studies with 264 participants) was not superior to placebo. SMD was ‐0.09 (95% CI ‐0.33 to 0.15) (P value 0.45). Herbal cannabis (two studies with 152 participants) was not superior to placebo. SMD was ‐0.28 (95% CI ‐0.64 to 0.08) (P value 0.13). </p> </section> </section> <section id="CD012182-sec-0130"> <h5 class="title">Very short‐term, short‐term and intermediate‐term duration studies</h5> <section id="CD012182-sec-0131"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>Cannabis‐based medicines in short‐term studies were not superior to placebo (three studies with 840 participants). RD was 0.06 (95% CI ‐0.01 to 0.13) (P value 0.05). Cannabis‐based medicines in intermediate‐term studies were not superior to placebo (three studies with 603 participants). RD was 0.04 (95% CI ‐0.03 to 0.11) (P value 0.24). </p> </section> <section id="CD012182-sec-0132"> <h6 class="title">Patient Global Impression of Change much or very much improved</h6> <p>Cannabis‐based medicines in very short‐term studies were not superior to placebo (two studies with 186 participants). RD was 0.17 (95% CI ‐0.18 to 0.51) (P value 0.34). Cannabis‐based medicines in intermediate‐term studies were not superior to placebo (three studies with 840 participants). RD was 0.05 (95% CI ‐0.00 to 0.11) (P value 0.05). </p> </section> <section id="CD012182-sec-0133"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Cannabis‐based medicines in very short‐term studies were not superior to placebo (three studies with 270 participants). RD was 0.03 (95% CI ‐0.03 to 0.09) (P value 0.34). Cannabis‐based medicines in short‐term studies were not superior to placebo (four studies with 478 participants). RD was 0.01 (95% CI ‐0.02 to 0.04) (P value 0.80). Cannabis‐based medicines in intermediate‐term studies were superior to placebo (five studies with 1120 participants). RD was 0.07 (95% CI 0.03 to 0.12) (P value 0.002). </p> </section> <section id="CD012182-sec-0134"> <h6 class="title">Serious adverse events</h6> <p>Cannabis‐based medicines in very short‐term studies were not superior to placebo (three studies with 270 participants). RD was ‐0.01 (95% CI ‐0.05 to 0.34) (P value 0.59). Cannabis‐based medicines in short‐term studies were not superior to placebo (five studies with 435 participants). RD was 0.00 (95% CI ‐0.02 to 0.02) (P value 1.0). Cannabis‐based medicines in intermediate‐term studies were superior to placebo (five studies with 1120 participants). RD was 0.03 (95% CI 0.00 to 0.06) (P value 0.05). </p> </section> <section id="CD012182-sec-0135"> <h6 class="title">Mean pain intensity</h6> <p>Cannabis‐based medicines in very short‐term studies were not superior to placebo (three studies with 268 participants). SMD was ‐0.13 (95% CI ‐0.38 to 0.12) (P value 0.31). Cannabis‐based medicines in short‐term studies were not superior to placebo (six studies with 453 participants). SMD was ‐0.63 (95% CI ‐1.31 to 0.05) (P value 0.07). Cannabis‐based medicines in intermediate‐term studies were not superior to placebo (five studies with 1109 participants). SMD was ‐0.09 (95% CI ‐0.20 to 0.03) (P value 0.31). </p> </section> </section> <section id="CD012182-sec-0136"> <h5 class="title">Published and unpublished trials with THC/CBD oromucosal spray</h5> <section id="CD012182-sec-0137"> <h6 class="title">Participant‐reported pain relief of 50% or greater</h6> <p>An analysis was not possible because the outcome was not reported by the unpublished trials. </p> </section> <section id="CD012182-sec-0138"> <h6 class="title">Patient Global Impression of Change much or very much improved</h6> <p>THC/CBD spray was superior to placebo in published trials (three studies with 655 participants). RD was 0.07 (95% CI 0.01 to 0.13) (P value 0.03). THC/CBD spray was not superior to placebo in unpublished trials (three studies with 437 participants). RD was 0.12 (95% CI ‐0.10 to 0.33) (P value 0.29). </p> </section> <section id="CD012182-sec-0139"> <h6 class="title">Withdrawals due to adverse events</h6> <p>There was a difference between THC/CBD spray and placebo in published trials (six studies with 935 participants). RD was 0.03 (95% CI 0.00 to 0.07) (P value 0.03). There was no difference between THC/CBD spray and placebo in unpublished trials (three studies with 437 participants). RD was 0.06 (95% CI ‐0.03 to 0.15) (P value 0.17). </p> </section> <section id="CD012182-sec-0140"> <h6 class="title">Serious adverse events</h6> <p>There was no difference between THC/CBD spray and placebo in published trials (six studies with 935 participants). RD was 0.01 (95% CI ‐0.01 to 0.03) (P value 0.48). There was no difference between THC/CBD spray and placebo in unpublished trials (three studies with 437 participants). RD was ‐0.00 (95% CI ‐0.04 to 0.04) (P value 1.0). </p> </section> <section id="CD012182-sec-0141"> <h6 class="title">Mean pain intensity</h6> <p>THC/CBD spray was superior to placebo in published trials (eight studies with 1069 participants). SMD was ‐0.46 (95% CI ‐0.42 to ‐0.01) (P value 0.05). THC/CBD spray was not superior to placebo in unpublished trials (three studies with 437 participants). SMD was ‐0.08 (95% CI ‐0.26 to 0.10) (P value 0.39). </p> </section> </section> <section id="CD012182-sec-0142"> <h5 class="title">Studies with high and unclear risk of bias due to sample size</h5> <p>Five of the 10 studies that reported the outcome 30% or more pain relief had treatment group sizes below 50 participants and we considered them at high risk of bias. Analysis of these five studies with 328 participants (24% of the total) showed an RD for pain relief of 30% or greater of 0.17 (95% CI 0.06 to 0.27); 40% of participants reported this outcome with cannabis‐based medicines and 26% with placebo. </p> <p>Five of the 10 studies that reported the outcome 30% or more pain relief had treatment group sizes above 50 but below 200 participants and we considered them at unclear risk of bias. Analysis of these four studies with 1018 participants (76% of the total) showed an RD for pain relief of 30% or greater of 0.05 (95% CI ‐0.00 to 0.11); 41% of participants reported this outcome with cannabis‐based medicines and 37% with placebo. </p> </section> </section> <section id="CD012182-sec-0143"> <h4 class="title">Heterogeneity</h4> <p>I² was less than 50% except for Patient Global Impression of Change (I² = 58%), mean pain intensity (I² = 55%), sleep problems (I² = 92%), psychological distress (I² = 66%), any adverse event (I² = 64%), nervous system disorders as adverse event (I² = 94%) and psychiatric disorders as adverse event (I² = 54%). We did not find clinical explanations for heterogeneity. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012182-sec-0144" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012182-sec-0144"></div> <section id="CD012182-sec-0145"> <h3 class="title" id="CD012182-sec-0145">Summary of main results</h3> <p>We included 16 studies, 2 to 26 weeks long, with 1750 participants. All studies compared cannabis‐based medicines with placebo except one study that compared synthetic THC with dihydrocodeine (DHC). Studies compared an oromucosal spray with a plant‐derived combination of THC and CBD (10 studies), inhaled herbal cannabis (two studies), synthetic THC (nabilone) (two studies) and plant‐derived THC (dronabinol) (two studies). </p> <p>All cannabis‐based medicines (at any dose) pooled together were superior to placebo for substantial (50% and more) (low‐ quality evidence) and moderate (30% and more) pain relief (moderate‐quality evidence), for global improvement (very low‐quality evidence), and in reduction of mean pain intensity (low‐quality evidence), sleep problems (low‐quality evidence), and psychological distress (low‐quality evidence). The effect sizes of mean pain intensity, sleep problems and psychological distress were clinically relevant. There was moderate‐quality evidence that more people dropped out due to adverse events with cannabis‐based medicines compared to placebo. There was low‐quality evidence that more people reported any adverse event and adverse events of the central nervous system and psychiatric disorders with all cannabis‐based medicines pooled together than with placebo. The effect size of adverse events of the nervous system disorders was clinically relevant. There was no difference between all cannabis‐based medicines pooled together and placebo in the frequency of serious adverse events (low‐quality evidence), for improvement of health‐related quality of life (low‐quality evidence) and dropouts due to lack of efficacy (moderate‐quality evidence). </p> <p>There was no high‐quality evidence suggesting that any cannabis‐based medicine (herbal cannabis, THC/CBD oromucosal spray, synthetic or plant‐based THC) was of value in treating people with chronic neuropathic pain. </p> </section> <section id="CD012182-sec-0146"> <h3 class="title" id="CD012182-sec-0146">Overall completeness and applicability of evidence</h3> <p>The overall completeness and applicability of the evidence were poor. The usefulness of the available evidence was limited because reporting quality was poor by current standards (<a href="./references#CD012182-bbs2-0106" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]'>Moore 2010a</a>). The reliability of the pooled results in general and of findings on nabilone in particular was limited because the results of three studies with nabilone have not been published and the results were not provided by the study authors on request (<a href="./references#CD012182-bbs2-0032" title="NCT00699634. Nabilone for the treatment of phantom limb pain. clinicaltrials.gov/ct2/show/NCT00699634?term=NCT00699634&amp;rank=1 (first posted 18 June 18). ">NCT00699634</a>; <a href="./references#CD012182-bbs2-0033" title="NCT01035281. Efficacy study of nabilone in the treatment of diabetic peripheral neuropathic pain. clinicaltrials.gov/ct2/show/NCT01035281?term=NCT01035281&amp;rank=1 (first posted 18 December 2009). ">NCT01035281</a>; <a href="./references#CD012182-bbs2-0034" title="NCT01222468. Effect of cannabinoids on spasticity and neuropathic pain in spinal cord injured persons. clinicaltrials.gov/ct2/show/NCT01222468?term=NCT01222468&amp;rank=1 (first posted 18 October 2010). ">NCT01222468</a>). The applicability of the evidence to routine clinical care was limited because all the included studies excluded people with current or historical substance abuse, or both, and major medical diseases. </p> </section> <section id="CD012182-sec-0147"> <h3 class="title" id="CD012182-sec-0147">Quality of the evidence</h3> <p>We found the evidence for most outcomes to be low quality because of indirectness (people with major medical disorders excluded) and inconsistent results. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. In addition, we found signs of publication bias. We found three industry‐sponsored studies of THC/CBD spray with negative results, which have not been fully published yet. We also found three studies of nabilone but the results were unknown; the study authors did not respond to our requests. Despite growing requirements for trial registration, full access to clinical trial data remains elusive (<a href="./references#CD012182-bbs2-0101" title="MintzesB , LexchinJ , QuintanoAS . Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin2015;116:43-53.">Mintzes 2015</a>). </p> <p>Six studies reviewed used a cross‐over design with a study duration between one to two weeks for each period, and cross‐over designs have methodological issues that could lead to bias (<a href="./references#CD012182-bbs2-0061" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). The short study duration limits their applicability. In addition, there are issues about the time needed (if any) for washout between treatment periods. Poor reporting limits their use in meta‐analysis, possibly with some biases (<a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). </p> <p>A large number of participants (7% to 91%) in the studies were former cannabis users. No subgroup comparisons (former cannabis users versus cannabis‐naive participants) were conducted by any study. A prospective observational study found that the rate of non‐serious adverse events among current cannabis users was lower than that among ex‐cannabis users or naive users (<a href="./references#CD012182-bbs2-0146" title="WareMA , WangT , ShapiroS , ColletJP , COMPASS study team. Cannabis for the management of pain: assessment of safety study (COMPASS). Journal of Pain2015;16:1233-42.">Ware 2015</a>).Therefore we do not know if the study results on efficacy and safety of the RCTs reviewed are valid for cannabis‐naive participants. </p> <p>People with chronic neuropathic pain exhibit a variety of pain‐related sensory symptoms and findings (<a href="./references#CD012182-bbs2-0042" title="BaronR , MaierC , AttalN , BinderA , BouhassiraD , CruccuG , et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain2017;158:261-72.">Baron 2017</a>). They use different descriptors for their pain (e.g. burning, tugging, pricking, cramping). None of the neuropathic pain scales available cover all potential descriptors of neuropathic pain (<a href="./references#CD012182-bbs2-0137" title="TysonSF , BrownP . How to measure pain in neurological conditions? A systematic review of psychometric properties and clinical utility of measurement tools. Clinical Rehabilitation2014;28:669-86.">Thyson 2014</a>). Eight of the studies reviewed used a neuropathic pain scale. However, none of the studies reported the effects of cannabis‐based medicines on the single dimensions of the neuropathic pain scales used. A recent study with botulinum toxin in peripheral neuropathic pain demonstrated a statistically significant effect on paroxysmal pain, but not on burning and deep pain (<a href="./references#CD012182-bbs2-0039" title="AttalN , deAndradeDC , AdamF , RanouxD , TeixeiraMJ , GalhardoniR , et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurology2016;15:555-65.">Attal 2016</a>). Therefore we do not know the efficacy of cannabis‐based medicines for specific qualities of neuropathic pain. </p> <p>Perhaps the biggest issue is that of the relatively small size of the studies. Nine of the 16 studies were at high risk of bias because of small size. There are issues over both random chance effects with small amounts of data, and potential bias in small studies, especially in pain (<a href="./references#CD012182-bbs2-0053" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304]">Dechartes 2013</a>; <a href="./references#CD012182-bbs2-0054" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA2014;312:623-30. [DOI: 10.1001/jama.2014.8166]">Dechartres 2014</a>; <a href="./references#CD012182-bbs2-0103" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>; <a href="./references#CD012182-bbs2-0122" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515]">Nüesch 2010</a>; <a href="./references#CD012182-bbs2-0136" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLOS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]">Thorlund 2011</a>). Cochrane Reviews have been criticised for perhaps over‐emphasising results of underpowered studies or analyses (<a href="./references#CD012182-bbs2-0036" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta-analyses: how common are false positive and false negative results?Interational Journal of Cardiology2013;168(2):1102-7. [DOI: 10.1016/j.ijcard.2012.11.048]">AlBalawi 2013</a>; <a href="./references#CD012182-bbs2-0140" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta-analyses: examination of underpowered studies in Cochrane Reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202]">Turner 2013</a>). On the other hand, it may be unethical to ignore potentially important information from small studies or to randomise more participants if a meta‐analysis including small, existing studies provided conclusive evidence. In this review, we chose to limit analyses to studies with a minimum of 10 participants per treatment group. Small studies may have influenced positive results in this review. For example, for moderate pain relief (at least 30% pain relief), the overall result was positive with an RD of 0.09 (0.03 to 0.15) in an analysis of 10 studies with 1566 participants, but the difference between cannabis‐based medicines and placebo was much larger in small studies. We had not initially planned this analysis, but examination of the forest plots demonstrated that for this and other outcomes, the elimination of small studies eliminated statistical significance. In view of the accumulating evidence regarding potential bias in small studies, the quality of the evidence for cannabis‐based medicines for treating neuropathic pain cannot be relied upon. </p> </section> <section id="CD012182-sec-0148"> <h3 class="title" id="CD012182-sec-0148">Potential biases in the review process</h3> <p>The absence of publication bias (unpublished trials showing no benefit of cannabis‐based medicines over placebo) can never be proved. We carried out a broad search for studies and feel it is unlikely that significant amounts of relevant data remain unknown to us. </p> <p>We might have overestimated the risk of bias of some studies that did not report some details of methodology (e.g. randomisation and blinding procedures). </p> <p>Most studies selected statistical methods (last observation carried forward, completer analysis) that bias results towards exaggerating the efficacy of drugs (<a href="./references#CD012182-bbs2-0114" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013b</a>). </p> <p>The influence of allowed co‐interventions (e.g. rescue medication) on positive effects and adverse events was unclear because type and dosage of co‐interventions were not clearly reported or controlled for. </p> <p>This systematic review included 1750 participants. To capture rare and potentially severe adverse events a larger data set would have been necessary. For example, to capture an adverse event with a frequency of 1:100,000, 300,000 participants' observations would have been necessary (<a href="./references#CD012182-bbs2-0037" title="AndersohnF , GarbeE . Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz2008;51:1134-55.">Andersohn 2008</a>). </p> </section> <section id="CD012182-sec-0149"> <h3 class="title" id="CD012182-sec-0149">Agreements and disagreements with other studies or reviews</h3> <p>We cannot share the optimistic conclusions of some reviews that cannabis‐based medicines are effective, well‐tolerated and safe in the treatment of chronic neuropathic pain (<a href="./references#CD012182-bbs2-0038" title="AndreaeMH , CarterGM , ShaparinN , SuslovK , EllisRJ , WareMA , et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. Journal of Pain2015;16(12):1221-32.">Andreae 2015</a>; <a href="./references#CD012182-bbs2-0047" title="BoychukDG , GoddardG , MauroG , OrellanaMF . The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral and Facial Pain and Headache2015;29(1):7-14.">Boychuk 2015</a>; <a href="./references#CD012182-bbs2-0098" title="LynchM , CampbellF . Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology2011;72:735-44.">Lynch 2011</a>). <a href="./references#CD012182-bbs2-0098" title="LynchM , CampbellF . Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology2011;72:735-44.">Lynch 2011</a> performed a qualitative systematic review on cannabis‐based medicines in chronic non‐cancer pain with 11 studies in chronic neuropathic pain and concluded that cannabis‐based medicines are "modestly" effective in neuropathic pain and did not lead to withdrawal from the study. <a href="./references#CD012182-bbs2-0047" title="BoychukDG , GoddardG , MauroG , OrellanaMF . The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral and Facial Pain and Headache2015;29(1):7-14.">Boychuk 2015</a> performed a qualitative analysis of 13 studies of cannabis‐based medicines in 771 participants with chronic neuropathic pain and concluded that cannabis‐based medicines should be considered as an alternative treatment for neuropathic pain. The authors made no definitive statement on tolerability and safety. <a href="./references#CD012182-bbs2-0038" title="AndreaeMH , CarterGM , ShaparinN , SuslovK , EllisRJ , WareMA , et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. Journal of Pain2015;16(12):1221-32.">Andreae 2015</a> performed an individual participant data analysis of 178 participants from five studies of inhaled cannabis. They calculated an NNTB of 6 (95% CI 3 to 14) for a more than 30% reduction in pain scores compared to placebo. Withdrawals due to adverse events were found to be rare. The differences to our rather cautious conclusions on the efficacy, tolerability and safety of cannabis‐based medicines in chronic neuropathic pain can be explained as follows. </p> <p> <ol id="CD012182-list-0008"> <li> <p>We performed a quantitative analysis, which included unpublished studies with negative results. The authors of the above‐mentioned reviews did not include the data of studies that are only available in databases. </p> </li> <li> <p>We excluded studies of very short‐term duration. <a href="./references#CD012182-bbs2-0038" title="AndreaeMH , CarterGM , ShaparinN , SuslovK , EllisRJ , WareMA , et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. Journal of Pain2015;16(12):1221-32.">Andreae 2015</a>; <a href="./references#CD012182-bbs2-0047" title="BoychukDG , GoddardG , MauroG , OrellanaMF . The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral and Facial Pain and Headache2015;29(1):7-14.">Boychuk 2015</a> and <a href="./references#CD012182-bbs2-0098" title="LynchM , CampbellF . Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology2011;72:735-44.">Lynch 2011</a> included two, one‐day studies (<a href="./references#CD012182-bbs2-0028" title="WilseyB , MarcotteT , DeutschR , GouauxB , SakaiS , GouauxB , et al. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain2013;14:136-48. ">Wilsey 2013</a>; <a href="./references#CD012182-bbs2-0027" title="WilseyB , MarcotteT , TsodikovA , MillmanJ , BentleyH , DonagheH . A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain2008;9:506-21. ">Wilsey 2008</a>), which we excluded because of short study duration. The European Medicines Agency requires that study duration for chronic neuropathic pain trials should be at least 12 weeks after a stable dose is achieved in order to exclude a transient effect (<a href="./references#CD012182-bbs2-0062" title="Guideline on clinical medicinal products intended for the treatment of neuropathic pain. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003478.pdf 2007 (Accessed May 2, 2015).">European Medicines Agency 2007</a>). </p> </li> <li> <p>We excluded studies that did not explicitly state that the pain was of neuropathic nature. This exclusion criterion was applied to some large studies in people with multiple sclerosis with spasticity as a major outcome. There is moderate‐quality evidence for the efficacy of cannabis‐based medicines to reduce spasticity symptoms (<a href="./references#CD012182-bbs2-0147" title="WhitingPF , WolffRF , DeshpandeS , Di NisioM , DuffyS . Cannabinoids for medical use: a systematic review and meta-analysis. JAMA2015;313:2456-73.">Whiting 2015</a>; <a href="./references#CD012182-bbs2-0149" title="ZettlUK , RommerP , HippP , PatejdlR . Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders2016;9:9-30.">Zettl 2016</a>). However, spasticity‐associated pain should not be mixed with central neuropathic pain (<a href="./references#CD012182-bbs2-0092" title="KoppelBS , BrustJC , FifeT , BronsteinJ , YoussofS , GronsethG , et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology2014;82:1556-63.">Koppel 2014</a>). </p> </li> <li> <p>We performed a detailed analysis of adverse events and withdrawals due to adverse events. </p> </li> </ol> </p> <p>On the other hand, our analyses do not support the conclusions of the Special Interest Group on Neuropathic Pain (NeuPSIG) of the International Association for the Study of Pain that cannabis‐based medicines are not effective in chronic neuropathic pain (<a href="./references#CD012182-bbs2-0065" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [DOI: 10.1016/S1474-4422(14)70251-0]">Finnerup 2015</a>). Our result that the use of cannabis‐based medicines is associated with an increased risk of short‐term adverse events, especially of the central nervous system, is in accordance with a systematic review of <a href="./references#CD012182-bbs2-0147" title="WhitingPF , WolffRF , DeshpandeS , Di NisioM , DuffyS . Cannabinoids for medical use: a systematic review and meta-analysis. JAMA2015;313:2456-73.">Whiting 2015</a> who analysed eight trials of cannabis‐based medicines in chronic neuropathic pain. </p> <p>We did not find a long‐term RCT with cannabis‐based medicines answering the question of long‐term efficacy and safety. One study with dronabinol included in the review added a 32‐week, open‐label extension period to the randomised controlled period. The study authors reported that, during long‐term follow‐up, pain intensities remained at a low level (range 2.5 to 3.8 of a 0 to 10 scale). The number of adverse events and dropouts due to adverse events was lower in the long‐term than in the randomised‐controlled period. "Mild signs" of drug dependency were documented for one participant (<a href="./references#CD012182-bbs2-0011" title="SchimrigkS , MarziniakM , NeubauerC , KuglerEM , WernerG , Abramov-SommarivaD . Dronabinol is a safe long-term treatment option for neuropathic pain patients. European Neurology2017;78:320-9. ">Schimrigk 2017</a>). THC/CBD oromucosal spray was investigated in a 38‐week, open‐label extension study. Three hundred and eighty participants with polyneuropathy associated with diabetes or allodynia entered this study from two previous RCTs. Participants received THC/CBD spray for a further 38 weeks in addition to their current analgesic therapy. The proportion of participants who reported at least a clinically relevant 30% improvement in pain continued to increase with time (up to nine months); at least half of all participants reported a 30% improvement at all time points. Improvements were observed for all secondary efficacy outcomes, including sleep quality, Patient Global Impression of Change and HRQoL. THC/CBD spray was well tolerated for the study duration and participants did not seek to increase their dose with time, with no new safety concerns arising from long‐term use (<a href="./references#CD012182-bbs2-0080" title="HoggartB , RatcliffeS , EhlerE , SimpsonKH , HovorkaJ , LejčkoJ , et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. Journal of Neurology2015;262:27-40.">Hoggart 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012182-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012182-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012182-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD012182-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 1: Pain relief of 50% or greater" data-id="CD012182-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 1: Pain relief of 50% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 2: Patient Global Impression much or very much improved" data-id="CD012182-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 2: Patient Global Impression much or very much improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 3: Withdrawals due to adverse events" data-id="CD012182-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 3: Withdrawals due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 4: Serious adverse events" data-id="CD012182-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 4: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 5: Pain relief of 30% or greater" data-id="CD012182-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 5: Pain relief of 30% or greater </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 6: Mean pain intensity" data-id="CD012182-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 6: Mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 7: Health‐related quality of life" data-id="CD012182-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 7: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 8: Sleep problems" data-id="CD012182-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 8: Sleep problems </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 9: Psychological distress" data-id="CD012182-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 9: Psychological distress </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 10: Withdrawals due to lack of efficacy" data-id="CD012182-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 10: Withdrawals due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 11: Any adverse event" data-id="CD012182-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 11: Any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 12: Specific adverse event: nervous system disorders" data-id="CD012182-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 12: Specific adverse event: nervous system disorders </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012182-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/urn:x-wiley:14651858:media:CD012182:CD012182-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 13: Specific adverse event: psychiatric disorders" data-id="CD012182-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_t/tCD012182-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Cannabis‐based medicines versus placebo at final treatment, Outcome 13: Specific adverse event: psychiatric disorders </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/media/CDSR/CD012182/image_n/nCD012182-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012182-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo for chronic neuropathic pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cannabis‐based medicines compared with placebo for chronic neuropathic pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: adults with chronic neuropathic pain </p> <p><b>Settings</b>: outpatient study centres and hospitals in Europe and North America </p> <p><b>Intervention</b>: cannabis‐based medicines (smoked cannabis; oral plant‐based (dronabinol) or synthetic tetrahydrocannabinol (THC) (nabilone); oromucosal spray of THC and cannabidiol (CBD)) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with intervention</b> </p> <p><b>95% CI</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Probable outcome with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect</b> </p> <p><b>Risk difference</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief of 50% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>209 per 1000</p> <p>(196 to 222)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (0.00 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1001 (8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 20 (11 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient Global Impression of Change much or very much improved</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>261 per 1000</p> <p>(246 to 276)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>211 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09 (0.01 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1092 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,3,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 11 (6 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> <p>(99 to 107)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.02 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1848 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 25 (16 to 50)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> <p>(63 to 69)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (‐0.01 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1876 (13 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH not calculated</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief of 30% or greater</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>377 per 1000</p> <p>(358 to 396)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>304 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09 (0.03 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1586 (10 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 11 (7 to 33)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events:</b> <b>nervous system disorder</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>611 per 1000</p> <p>(576 to 644)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.18 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1304 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 3 (2 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events:</b> <b>psychiatric disorders</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>165 per 1000</p> <p>(156 to 174)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (0.06 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1314 (9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 10 (7 to 16)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Abbreviations</b> : <br/><b>CI</b> : Confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>NNTH</b> : number needed to treat for an additional harmful outcome; <b>RD</b>: risk difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b>: we are very confident that the true effect lies close to that of the estimate of the effect; </p> <p><b>Moderate quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different; </p> <p><b>Low quality</b>: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect; </p> <p><b>Very low quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded once: indirectness. People with current or historical substance abuse, or both, and major medical diseases excluded.<br/><sup>2</sup> Downgraded once: imprecision. CI included zero.<br/><sup>3</sup> Downgraded once: inconsistency. I²&gt;50%. </p> <p><sup>4</sup> Downgraded once: Publication bias. All studies funded by the manufacturer of the drug. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo for chronic neuropathic pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/full#CD012182-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012182-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cannabis‐based medicines versus placebo at final treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain relief of 50% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.00, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.06, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.54, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Patient Global Impression much or very much improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.01, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.09, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.02, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Central or peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.22, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.02, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.10, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.04, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Peripheral pain ‐ HIV polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.13, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.7 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.8 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.19, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Peripheral pain ‐ chemotherapy‐induced neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.10, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.05, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 Peripheral pain ‐ HIV polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.07, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 Peripheral pain ‐ polyneuropathies of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.8 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Pain relief of 30% or greater <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.03, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.16, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 Peripheral pain ‐ HIV polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.05, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.5 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.06, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.6 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.60, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.25, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.41, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.86, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.27, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.5 Peripheral pain ‐ HIV polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.94, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.6 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.79, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.7 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.75, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.8 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.71, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.10, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.27, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.37, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.06, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.42, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.5 Peripheral pain of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.26, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.6 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.35, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐0.90, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.21, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.41, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.38, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.78, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐2.17, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.78, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Psychological distress <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.61, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.65, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐1.78, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.97, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.62, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.5 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.80, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.02, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Peripheral pain ‐ plexus injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.04, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.09, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.18, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.05, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.5 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.06, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Specific adverse event: nervous system disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.18, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.38, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Peripheral pain ‐chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.5 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.19, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.6 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.15, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Specific adverse event: psychiatric disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.06, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Central pain ‐ multiple sclerosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.05, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Central pain ‐ spinal cord injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.06, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 Peripheral pain ‐ chemotherapy‐induced polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.06, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 Peripheral pain ‐ diabetic polyneuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.5 Peripheral pain ‐ polyneuropathy of various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.14, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.6 Central and peripheral pain ‐ various aetiologies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.05, 0.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cannabis‐based medicines versus placebo at final treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012182.pub2/references#CD012182-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012182.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012182-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012182-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012182-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012182-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012182-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD012182-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012182-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012182\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012182\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012182\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012182\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012182\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012182.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012182.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012182.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012182.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012182.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728235472"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012182.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728235476"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012182.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebf871ac2f46e',t:'MTc0MDcyODIzNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 